UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK

In re:
PURDUE PHARMA L.P., et al.,
Debtors. ¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered) Objection Deadline: February 25, 2021 at 5:00 p.m. ET

FIFTEENTH MONTHLY FEE APPLICATION OF DECHERT LLP FOR ALLOWANCE OF COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF EXPENSES AS COUNSEL TO THE DEBTORS AND DEBTORS IN POSSESSION FOR THE PERIOD FROM NOVEMBER 1, 2020 THROUGH NOVEMBER 30, 2020

Name of Applicant:	Dechert LLP
Authorized to Provide Professional Services to:	Purdue Debtors and
	Debtors in Possession
Effective Date of Retention:	November 21, 2019
	Nunc Pro Tunc to
	September 15, 2019
Period for which compensation and	November 1, 2020
reimbursement is sought:	through November 30,
	2020
Amount of compensation sought as actual, reasonable, and	
necessary:	\$569,755.58 ²
Eighty percent of actual, reasonable and necessary compensation:	\$455,804.46

The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

This amount reflects a reduction in fees in the amount of \$137,991.92 on account of voluntary discounts for aggregate fees as described in the *Application of Debtors for Authority to Retain and Employ Dechert LLP as Special Counsel to the Debtors* Nunc Pro Tunc *to the Petition Date* [Docket No. 424] (the "**Retention Application**") and *Dechert LLP's First Notice of Increase in Hourly Rates for Patent Services* [Docket No. 965] (the "**Notice of Increased Patent Fees**").

Amount of expense reimbursement sought as actual, reasonable, and necessary:	\$181,654.82
This is a(n): X Monthly Interim Final application	on.
Is this the first monthly application?Yes _X_No	
This application includes 55.7 hours with a value of \$22.427.50 in over	

This application includes 55.7 hours with a value of \$23,427.50 incurred in connection with the preparation of Fee Applications for the Debtors.

Compensation by Individual for Debtors for Litigation Services

Name of Professional Person	Position of the Applicant	Year of Obtaining License to Practice (if Applicable)	Hourly Billing Rate (Including Changes) ³	Total Billed Hours	Total Compensation
Sheila L Birnbaum	Partner	1965	1,350.00	139.40	188,190.00
Hayden A. Coleman	Partner	1985	915.00	130.10	119,041.50
Hope S. Freiwald	Partner	1980	1,090.00	4.00	4,360.00
Mara C. Cusker Gonzalez	Partner	2005	890.00	19.40	17,751.00
Nathan E. Hoffman	Partner	2000	915.00	0.60	549.00
Paul A. LaFata	Counsel	2007	890.00	26.20	23,318.00
Sara B. Roitman	Partner	2010	890.00	121.40	111,081.00
Erik W. Snapp	Partner	1995	915.00	3.60	3,294.00
Jonathan S. Tam	Counsel	2009	890.00	9.50	8,455.00
Shmuel Vasser	Partner	1988	915.00	12.80	11,712.00
Christopher R. Boisvert	Counsel	2009	890.00	18.50	16,465.00
Danielle Gentin Stock	Counsel	1999	890.00	95.20	84,728.00
Michelle K. Yeary	Counsel	1995	890.00	1.50	1,335.00
Alyssa C. Clark	Associate	2017	725.00	6.00	4,350.00
Alison S. Cooney	Associate	2013	840.00	11.70	9,828.00
Kim, Mary H.	Associate	2015	800.00	2.80	2,240.00
Sarah Magen	Associate	2012	855.00	7.40	6,327.00
Jenna C. Newmark	Associate	2011	855.00	38.80	33,174.00
Katherine Norman	Associate	2019	565.00	3.60	2,034.00
Theodore E. Yale	Associate	2017	725.00	21.70	15,732.50
Lindsay N. Zanello	Associate	2015	800.00	0.50	400.00

As described in the Retention Application, these billing rates reflect voluntary discounts of 1% to 24% for senior partners, 6% to 13% for junior partners, 1% to 5% for counsel, and 5% to 10% for associates.

Nicholas C. Dean	Staff Attorney		365.00	7.90	2,883.50
Antonella Capobianco-					
Ranallo	Legal Asst	N/A	200.00	3.00	600.00
Matthew B. Stone	Legal Asst	N/A	200.00	38.30	7,660.00
Danielle A. Torrice	Legal Asst	N/A	200.00	0.30	60.00
Denise Neris	Project Asst	N/A	155.00	12.20	1,891.00
Cohen, Claudia	Other	N/A	185.00	0.10	18.50
Total				737.20	\$678,101.00
20% Volume Discount					(\$135,620.20)
Discounted Total					\$542,480.80
Total Amount					
Requested Herein					\$433,984.64

Compensation by Individual for Debtors for Patent Services

Name of Professional Person	Position of the Applicant	Year of Obtaining License to Practice (if Applicable)	Hourly Billing Rate (Including Changes) ⁴	Total Billed Hours	Total Compensation
Samuel B. Abrams	Partner	1981	885.00	10.00	8,850.00
Blaine M. Hackman	Associate	2012	740.00	17.40	12,876.00
Donna Marks	Legal Assistant	N/A	305.00	1.30	396.50
Sherrice T. Breland	Legal Assistant	N/A	285.00	26.40	7,524.00
Total				55.10	\$29,646.50
8% Volume Discount ⁵					(\$2,371.72)
Discounted Total					\$27,274.78
Total Amount Requested Herein					\$21,819.82

The blended hourly billing rate of professionals for all services provided during the Fee Period is \$719.12.

⁴ As described in Notice of Increased Patent Fees, these billing rates reflect voluntary discounts of 10% to 28% for partners, 19% for counsel, 22% for associates, 0% to 18% for paraprofessionals, and 7% to 10% for patent agents.

As described in the Notice of Increased Patent Fees, Dechert will apply an 8% discount for aggregate fees and this aggregate discount will apply to all timekeepers.

Compensation by Project Category for Debtors

Code	Project Category	Total Hours	Total Fees
B110	Case Administration	0.90	178.50
B160	Fee/Employment Applications	55.70	23,427.50
B165	Budgeting (case)	5.20	4,186.00
L120	Analysis/Strategy	214.10	207,562.00
L130	Experts/Consultants	33.50	29,838.50
L140	Document/File Management	2.50	500.00
L150	Budgeting	1.40	1,281.00
L160	Settlement/Non-Binding ADR	135.80	152,301.50
L190	Other Case Assessment, Development and Administration	15.90	4,630.50
L210	Pleadings	34.10	34,478.50
L220	Preliminary Injunctions/Provisional Remedies	1.40	1,246.00
L230	Court Mandated Conferences	37.30	37,539.50
L310	Written Discovery	19.10	18,638.50
L320	Document Production	16.10	15,525.50
L330	Depositions	142.80	131,359.50
L350	Discovery Motions	0.70	945.00
L410	Fact Witnesses	7.50	6,862.50
L440	Other Trial Preparation and Support	13.20	7,600.50
P260	Intellectual Property	55.10	29,646.50
Total		792.30	\$707,747.50 ⁶

⁶ This amount reflects the discounted billing rates but not the discounts for aggregate fees.

Expense Summary for Debtors

Expenses Category	Total
Expenses Category	Expenses
Consultants Fees ⁷	178,580.42
Court Costs	210.00
Docket Fees	5.40
Document	
Storage/Retrieval	0.00
Federal Express Charges	17.70
Filing Fees and Related	2,016.88
Overtime Dinner Expense	20.00
Taxi Fare	39.60
Westlaw Search Fees	764.82
Total	\$181,654.82

These consultant fees are Ankura Consulting Group, LLC, a firm that manages a document hosting platform necessary for Dechert to provide legal services to the Debtors.

UNITED STATES BANKRUPTCY CO)URT
SOUTHERN DISTRICT OF NEW YO	RK

•	
In	ro.
	16.

PURDUE PHARMA L.P., et al.,

Debtors.1

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered) Objection Deadline: February 25, 2021 at 5:00 p.m. ET

FIFTEENTH MONTHLY FEE APPLICATION OF DECHERT LLP FOR ALLOWANCE OF COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF EXPENSES AS COUNSEL TO THE DEBTORS AND DEBTORS IN POSSESSION FOR THE PERIOD FROM NOVEMBER 1, 2020 THROUGH NOVEMBER 30, 2020

By this monthly fee application (the "Application"), pursuant to sections 330 and 331 of title 11 of the United States Code (the "Bankruptcy Code") and Rule 2016 of the Federal Rules of Bankruptcy Procedure (the "Bankruptcy Rules"), Dechert LLP ("Dechert") hereby moves this Court for discounted reasonable compensation for professional legal services rendered as attorneys to the Debtors in the amount of \$455,804.46 together with reimbursement for actual and necessary expenses incurred in the amount of \$181,654.82, for the period commencing November 1, 2020 through and including November 30, 2020 (the "Fee Period"). In support of the Application, Dechert respectfully represents as follows:

The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

- 1. Dechert was employed under a general retainer to represent the Debtors as bankruptcy counsel in connection with these chapter 11 cases pursuant to an order entered by this Court on November 21, 2019 [Docket No. 525] (the "Retention Order"). The Retention Order authorized Dechert to be compensated on an hourly basis and to be reimbursed for actual and necessary out-of-pocket expenses.
- 2. All services for which compensation is requested by Dechert were performed for or on behalf of the Debtors.

SUMMARY OF SERVICES RENDERED

- 3. Attached hereto as **Exhibit A** is a detailed statement of fees incurred during the Fee Period showing the amount of \$569,755.58,² of which \$455,804.46 is requested for fees in this Application. **Exhibit B** is a detailed statement of expenses paid during the Fee Period showing the amount of \$181,654.82 for reimbursement of expenses.
- 4. The services rendered by Dechert during the Fee Period are grouped into the categories set forth in **Exhibit A**. The attorneys and paralegals who rendered services relating to each category are identified, along with the number of hours for each individual and the total compensation sought for each category, in the attachments hereto.

DISBURSEMENTS

5. Dechert has incurred out-of-pocket disbursements during the Fee Period in the amount of \$181,654.82. This disbursement sum is broken down into categories of charges, including, among other things, document hosting and management, temporary employee

This amount reflects a reduction in fees in the amount of \$137,991.92 on account of voluntary discounts for aggregate fees as described in the *Application of Debtors for Authority to Retain and Employ Dechert LLP as Special Counsel to the Debtors* Nunc Pro Tunc *to the Petition Date* [Docket No. 424] (the "**Retention Application**") and *Dechert LLP's First Notice of Increase in Hourly Rates for Patent Services* [Docket No. 965] (the "**Notice of Increased Patent Fees**").

expenses, expert consulting charges, telephone and telecopier toll and other charges, mail and express mail charges, special or hand delivery charges, document processing, photocopying charges, charges for mailing supplies (including, without limitation, envelopes and labels) provided by Dechert to outside copying services for use in mass mailings, travel expenses, expenses for "working meals," computerized research, and transcription costs.

- 6. A complete review of the expenses incurred for the Fee Period may be found in the attachments hereto as **Exhibit B**. To the extent such itemization is insufficient to satisfy the requirements of Rule 2016-1(a) of the Local Rules of Bankruptcy Practice and Procedure of the United States Bankruptcy Court for the Southern District of New York (the "**Local Rules**"), Dechert respectfully requests that the Court waive strict compliance with such rule.
- 7. Costs incurred for computer assisted research are not included in Dechert's normal hourly billing rates and, therefore, are itemized and included in Dechert's disbursements. Pursuant to Local Rule 2016-1, Dechert represents that its rate for duplication is \$.10 per page, there is no charge for incoming or outgoing telecopier transmissions, and there is no surcharge for computerized research.

VALUATION OF SERVICES

- 8. Attorneys and paraprofessionals of Dechert have expended a total of 792.3 hours in connection with the Debtors' chapter 11 cases during the Fee Period.
- 9. The amount of time spent by each of these persons providing services to the Debtors for the Fee Period is fully set forth in detail in **Exhibit A**. These are Dechert's discounted hourly rates for compensation in this case, as reflected in the Retention Application. The Discounted value of the services rendered by Dechert for the Fee Period as counsel for the

Debtors in these cases under chapter 11 is \$569,755.58, of which \$455,804.46 is requested for fees in this Application.

- 10. Dechert believes that the time entries included in **Exhibit A** attached hereto and the expense breakdown set forth in **Exhibit B** attached hereto are in compliance with the requirements of Local Rule 2016-1.
- 11. In accordance with the factors enumerated in section 330 of the Bankruptcy Code, the amount requested is fair and reasonable given (a) the complexity of this case, (b) the time expended, (c) the nature and extent of the services rendered, (d) the value of such services, and (e) the costs of comparable services other than in a case under this title.
- 12. This Application covers the period of November 1, 2020 through and including November 30, 2020 with respect to the Debtors. Dechert has and will continue to perform additional necessary services for the Debtors subsequent to November 30, 2020, for which Dechert will file subsequent fee applications.

[Remainder of page left intentionally blank]

CONCLUSION

WHEREFORE, Dechert respectfully requests that (a) allowance be made to it in the sum of \$455,804.46 as compensation for necessary professional services rendered to the Debtors for the Fee Period, and the sum of \$181,654.82 for reimbursement of actual necessary costs and expenses incurred during the Fee Period, (b) such other further relief as this Court may deem just and proper.

Dated: February 11, 2021 Respectfully submitted,

/s/ Shmuel Vasser

Shmuel Vasser DECHERT LLP 1095 Avenue of the Americas

New York, New York 10036 Telephone: (212) 698-3500 Facsimile: (212) 698-3599

Attorneys for Debtors and Debtors in Possession

19-23649-shl Doc 2376 Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 11 of 92

UNITED STATES BANKRUPTCY COURT	1
SOUTHERN DISTRICT OF NEW YORK	

In re: Chapter 11

PURDUE PHARMA L.P., et al.,

Debtors.1

Case No. 19-23649 (RDD)

(Jointly Administered)

VERIFICATION OF SHMUEL VASSER

- I, Shmuel Vasser, Esquire, hereby declare the following under penalty of perjury:
- 1. I am a Partner in the applicant firm, Dechert LLP, and have been admitted to the bar of New York since 1991.
- 2. I have personally performed some of the legal services rendered by Dechert LLP as counsel for the Debtors, and I am generally familiar with all other work performed on behalf of the Debtors by the lawyers and paraprofessionals in the firm.
- 3. The facts set forth in the foregoing Application are true and correct to the best of my knowledge, information and belief.

[Remainder of page left intentionally blank]

The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

4. I hereby certify under 28 U.S.C. § 1746 that the foregoing is true and correct to the best of my knowledge, information, and belief.

Dated: February 11, 2021 Respectfully submitted,

/s/ Shmuel Vasser

Shmuel Vasser
DECHERT LLP
1095 Avenue of the Americas
New York, New York 10036
Telephone: (212) 698-3500

Facsimile: (212) 698-3599 shmuel.vasser@dechert.com

Attorneys for Debtors and Debtors in Possession

EXHIBIT A

Description of Legal Services



1095 Avenue of the Americas New York, NY 10036-6797 FED. ID. 23-1425587 www.dechert.com

Purdue Pharma L.P. 201 Tresser Blvd. Stamford, CT 06901 February 3, 2021 Invoice Number 1010003211

Firm Client Matter Number: 399631.178405

Client Name: Purdue Pharma L.P.

Matter Name: Mediation & Settlement, Claims Evaluation, and Operations

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL FEES THIS INVOICE	630,089.50
Less 20% Discount	(126,017.90)
NET TOTAL FEES THIS INVOICE	504,071.60
TOTAL DISBURSEMENTS THIS INVOICE	1,114.40
TOTAL AMOUNT DUE FOR THIS INVOICE	USD 505,186.00

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 15 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

PROFESSIONAL SERVICES RENDERED:

<u>Date</u>	TIMEKEEPER	Hours Task	ACTIVITY	<u>Amount</u>
B110 – Case	Administration			
11/11/20	Matthew Stone	0.70 B	3110 A101	140.00
	Calendar omnibus hearing dates appearances for attorneys at 11, Morales regarding same (.1).		•	
11/19/20	Matthew Stone	0.10 B	3110 A101	20.00
	Calendar interim fee application	hearing for attorneys.		
B110 SUBTO	TAL HOURS AND FEES:	0.80		160.00
L120 – Analy	sis/Strategy			
11/01/20	Jenna Newmark	0.50 l	L120 A104	427.50
	Review and analyze materials refor claims analysis (0.5).	garding third party payor ar	nd hospital claims	
11/02/20	Sheila Birnbaum	0.30 l	L120 A105	405.00
	Telephone conference with D. St	ock regarding monitor.		
11/02/20	Sheila Birnbaum	1.00 l	L120 A104	1,350.00
	Review materials on suspicious of letters and material (0.4).	order monitoring (0.6); revie	ew insurance	
11/02/20	Hayden Coleman	0.40 l	L120 A104	366.00
	Review and analyze case update against certain current and form			
11/02/20	Sara Roitman	1.00 l	L120 A104	915.00
	Draft summary of third-party pa	yor damages claims.		
11/03/20	Sheila Birnbaum	2.00 l	L120 A104	2,700.00
	Review newly filed documents fr UCC (0.4); review media reports Monitoring (0.5).		• • •	
11/03/20	Sheila Birnbaum	0.90 l	L120 A106	1,215.00
	Telephone conference with Purd issues (0.9).	lue team regarding case sta	tus and litigation	
11/03/20	Hayden Coleman	0.30 l	L120 A104	274.50
	Review FDA advisory committee Strategies (0.3).	position on Risk Evaluation	and Mitigation	
11/03/20	Hayden Coleman	1.10 l	L120 A106	1,006.50
	Plan for and participate in weekl retained counsel (1.1).	y principals call with client a	and other	

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 16 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 3

<u>Date</u>	TIMEKEEPER	Hours Task		<u>ACTIVITY</u>	<u>Amount</u>
11/03/20	Danielle Gentin Stock	1.00	L120	A107	890.00
	Provide proposed DEA Rule to the Monitor ((0.6); correspond with co-counsel regarding		pose	d DEA Rule	
11/03/20	Danielle Gentin Stock	0.90	L120	A107	801.00
	Participate on client update call with co-cour	nsel (0.9).			
11/04/20	Sheila Birnbaum	2.30	L120	A104	3,105.00
	Review insurance materials including complete report (1.2); review MDL report (0.3).	int (0.8); reviev	w mo	nitor's draft	
11/04/20	Sara Roitman	0.80	L120	A105	732.00
	Communicate with Dechert team regarding of	claims/valuatio	n ana	lysis.	
11/05/20	Sheila Birnbaum	1.40	L120	A104	1,890.00
	Review NAACP materials (0.6); review Monit	or's report (0.8	s).		
11/05/20	Hayden Coleman	0.40	L120	A104	366.00
	Review and analyze FDA conclusion regardin Evaluation and Mitigation Strategies (REMS)	-	of Ri	sk	
11/05/20	Mara Cusker Gonzalez	0.70	L120	A109	640.50
	Prepare for (.2) and attend (.5) meeting with valuation strategy and commercial claims.	litigation coun	sel re	garding	
11/05/20	Sara Roitman	0.30	L120	A106	274.50
	Communicate with client regarding NAACP re	equests.			
11/05/20	Sara Roitman	2.50	L120	A105	2,287.50
	Communicate with Dechert team regarding of	claim/valuation	anal	ysis.	
11/05/20	Sara Roitman	1.70	L120	A104	1,555.50
	Analyze issues regarding third-party payor, h syndrome claimants' analysis (1.7).	ospital, and ne	onata	al abstinence	
11/05/20	Lindsay Zanello	0.10	L120	A107	80.00
	Communicate with local counsel regarding V	Vest Virginia ca	ses.		
11/05/20	Lindsay Zanello	0.10	L120	A105	80.00
	Communicate internally regarding West Virg	inia cases.			
11/05/20	Danielle Gentin Stock	1.30	L120	A106	1,157.00
	Correspond with client regarding Monitor's i client and co-counsel regarding proposed DE call with client to discuss case updates (0.7).				
11/05/20	Danielle Gentin Stock	0.80	L120	A104	712.00
	Review and analyze initial findings by the Mopayor data (0.4).	onitor (0.4); res	earch	third-party	
11/05/20	Danielle Gentin Stock	0.70	L120	A105	623.00
	Confer internally regarding claims analysis (C	.7).			

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 17 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 4

DATE	Тімекеереп	Hours Tasi	<u>K</u>	<u>ACTIVITY</u>	Amount
11/06/20	Sheila Birnbaum	2.10	L120	A104	2,835.00
	Review Purdue updates summary (0.4); review materials for other settlements (0.4); with monitors report (0.5).			• •	
11/06/20	Sheila Birnbaum	0.50	L120	A108	675.00
	Telephone conference with NAACP represer	itatives (0.5).			
11/06/20	Hayden Coleman	1.60	L120	A107	1,464.00
	Conference call with Dechert and DPW regal related legal issues (0.6); conference call wit DPW regarding claims estimation analysis (1	h Cornerston			
11/06/20	Hayden Coleman	0.30	L120	A105	274.50
	Communicate with Dechert team regarding monitoring claims.	neonatal abs	tinence	syndrome	
11/06/20	Hayden Coleman	0.20	L120	A104	183.00
	Review NY appellate ruling regarding Allerga Pfizer over sale of opioid products (0.2).	ın indemnific	ation su	uit against	
11/06/20	Mara Cusker Gonzalez	2.60	L120	A108	2,379.00
	Prepare for and attend conferences with bar counsel, and consultants regarding claim and (1.2); confer with litigation team regarding lessame (1.4).	alysis and val	uation :	strategy	
11/06/20	Sara Roitman	3.50	L120	A107	3,202.50
	Communicate with bankruptcy co-counsel a valuation analysis.	nd consultan	ts regar	rding	
11/06/20	Sara Roitman	0.80	L120	A105	732.00
	Communicate with Dechert team regarding valuation analysis.	statute of lim	nitation	s exercise for	
11/06/20	Theodore Yale	1.20	L120	A102	870.00
	Research and analysis regarding statute of li and third party payers.	mitations issi	ues for	hospitals	
11/06/20	Lindsay Zanello	0.10	L120	A107	80.00
	Communicate with local counsel regarding V	Vest Virginia	cases.		
11/06/20	Christopher Boisvert	0.50	L120	A105	445.00
	Telephone conference with M. Cusker Gonza memorandum on third party payors and star		_	_	
11/06/20	Danielle Gentin Stock	0.60	L120	A105	534.00
	Correspond internally, with client and co-correlated to the Monitor (0.5); correspond intefindings (0.1).	_	_	•	
11/06/20	Danielle Gentin Stock	0.30	L120	A104	267.00
	Review and analyze Monitor findings (0.3).				

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 18 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 5

DATE	<u>Timekeeper</u>	Hours Tasi	<u>K</u>	A CTIVITY	AMOUNT		
11/06/20	Danielle Gentin Stock	0.20	L120	A106	178.00		
	Correspond with client regarding Monitor findings (0.2).						
11/06/20	Jonathan Tam	0.70	L120	A107	623.00		
	Strategize and confer with co-counsel regard	ding estimation	on anal	ysis (0.7).			
11/09/20	Sheila Birnbaum	1.00	L120	A104	1,350.00		
	Review monitor report and emails regarding regarding insurance (0.3).	same (0.7);	review	emails			
11/09/20	Hayden Coleman	7.50	L120	A104	6,862.50		
	Attend to privilege and waiver issues.						
11/09/20	Sara Roitman	0.70	L120	A107	640.50		
	Communicate with consultants regarding to	rt claims valu	ation a	nalysis.			
11/09/20	Sara Roitman	0.80	L120	A105	732.00		
	Communicate with Dechert team regarding	claim liquida	tion pro	ocess.			
11/09/20	Sara Roitman	0.40	L120	A103	366.00		
	Draft summary regarding plaintiffs' request to Negotiation Class appeal (.4).	for an en ban	ic heari	ng in the			
11/09/20	Christopher Boisvert	0.90	L120	A103	801.00		
	Draft memorandum regarding statute of lim payor cases.	itations issue	s in thi	rd party			
11/09/20	Danielle Gentin Stock	0.10	L120	A105	89.00		
	Correspond internally regarding Monitor find	dings.					
11/09/20	Danielle Gentin Stock	0.40	L120	A106	356.00		
	Confer and correspond with client regarding steps.	Monitor's fi	ndings a	and next			
11/09/20	Danielle Gentin Stock	1.00	L120	A104	890.00		
	Review and fact check Monitor's findings (1.	0).					
11/10/20	Sheila Birnbaum	0.30	L120	A106	405.00		
	Telephone conference with Purdue team reg	garding insur	ance iss	sues (0.3).			
11/10/20	Sheila Birnbaum	1.10	L120	A104	1,485.00		
	Review Congressional letter and emails (0.3) response to Congressional letter (0.5).	; review upd	ates (0.	3); review			
11/10/20	Sheila Birnbaum	0.30	L120	A108	405.00		
	Telephone conference with representative consurance issues (0.3).	of consenting	states	regarding			
11/10/20	Hayden Coleman	0.50	L120	A108	457.50		
	Participate in WebEx with Cornerstone and I claims.	Brattle Group	regard	ling Hospital			

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 19 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 6

DATE	TIMEKEEPER	Hours Tas	<u>sk</u>	<u>ACTIVITY</u>	AMOUNT
11/10/20	Hayden Coleman	0.90	L120	A104	823.50
	Review and analyze DEA proposal for expansional mechanisms (0.4); review and comment on House and Senate letters (0.4); review joind consolidated cases (0.2).	company's s	tatemer	nt regarding	
11/10/20	Hayden Coleman	1.20	L120	A106	1,098.00
	Prepare for and participate in weekly princip	oals coordina	ating cal	l.	
11/10/20	Sara Roitman	1.10	L120	A106	1,006.50
	Confer with insurance counsel and client reglitigation.	garding strat	egy in in	surance	
11/10/20	Christopher Boisvert	5.30	L120	A102	4,717.00
	Conduct legal research on third party payor	statute of lin	mitation	s. issues.	
11/10/20	Danielle Gentin Stock	0.80	L120	A106	712.00
	Confer and correspond with client regarding checking (0.8).	g Monitor fin	ndings ar	nd fact-	
11/10/20	Danielle Gentin Stock	0.10	L120	A107	89.00
	Correspond with co-counsel and client regard (0.1).	rding filing o	f Monito	or report	
11/10/20	Danielle Gentin Stock	1.00	L120	A107	890.00
	Participate on client update call with co-cou	nsel (1.0).			
11/11/20	Sheila Birnbaum	1.10	L120	A104	1,485.00
	Review monitor reports and recommendation parties and emails regarding same (0.3).	on (0.8); revi	iew Coui	t's note to	
11/11/20	Sheila Birnbaum	0.70	L120	A109	945.00
	Attend board meeting with monitor reporting	ng.			
11/11/20	Hayden Coleman	0.60	L120	A107	549.00
	Communicate with Cornerstone, Dechert, an claims.	nd DPW rega	arding H	ospital	
11/11/20	Hope Freiwald	0.90	L120	A104	981.00
	Review hospital-related damages data and r communicate with S. Roitman regarding san		ms (.7);		
11/11/20	Sara Roitman	1.00	L120	A104	915.00
	Analyze hospital claimants' damages models	s and claim ι	universe		
11/11/20	Sara Roitman	1.00	L120	A107	915.00
	Communicate with bankruptcy co-counsel a hospital claimant valuation analysis and scolissues regarding same.		_	•	
11/11/20	Theodore Yale	0.20	L120	A102	145.00
	Research regarding statute of limitations iss	ues.			
11/11/20	Danielle Gentin Stock	0.10	L120	A105	89.00
	Correspond internally regarding recent state	e court filing	(0.1).		

Filed 02/11/21 Entered 02/11/21 12:25:06 Pg 20 of 92 Main Document

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211

Page 7

DATE	TIMEKEEPER	Hours Tas	К	ACTIVITY	Amount		
11/11/20	Danielle Gentin Stock	0.10	_ L120	A106	89.00		
	Correspond with client regarding service agent (0.1).						
11/11/20	Danielle Gentin Stock	0.10	L120	A107	89.00		
	Correspond with co-counsel regarding state	-specific que	ry (0.1).				
11/11/20	Danielle Gentin Stock	2.40	L120	A109	2,136.00		
	Prepare for (1.7) and attend Board of Direct	ors Meeting	(0.7).				
11/12/20	Sheila Birnbaum	2.30	L120	A109	3,105.00		
	Attend Ad Hoc Committee structure present	tation.					
11/12/20	Sheila Birnbaum	0.30	L120	A105	405.00		
	Call with Dechert lawyers regarding case sta	tus.					
11/12/20	Hayden Coleman	1.60	L120	A107	1,464.00		
	Participate in WebEx with DPW, Cornerstone personal injury claims (1.0); communicate w claims (0.3); communicate with DPW and Deabstinence syndrome claims (0.3).	rith DPW tear	m regar	ding hospital			
11/12/20	Hayden Coleman	0.50	L120	A105	457.50		
	Conference call with Dechert team regarding strategy.	g ongoing ass	signmer	nts and			
11/12/20	Mara Cusker Gonzalez	0.50	L120	A105	457.50		
	Confer with litigation team regarding legal revaluation and disclosure strategy regarding of						
11/12/20	Sara Roitman	2.90	L120	A104	2,653.50		
	Analyze personal injury, hospital, and neona monitoring claimants, and Third party payor analyses strategies.		-				
11/12/20	Theodore Yale	7.50	L120	A102	5,437.50		
	Research regarding statutes of limitations de hospital claims.	efenses for th	nird-par	ty payer and			
11/12/20	Christopher Boisvert	1.70	L120	A102	1,513.00		
	Conduct legal research regarding third party limitations issues.	payor plaint	iffs and	statute of			
11/12/20	Danielle Gentin Stock	0.50	L120	A106	445.00		
	Correspond (.1) and confer (.4) with client re	egarding case	e update	es.			
11/12/20	Danielle Gentin Stock	0.90	L120	A107	801.00		
	Confer with co-counsel regarding claims and	ılysis.					
11/12/20	Danielle Gentin Stock	0.30	L120	A106	267.00		
	Confer with client regarding Monitor finding	s.					
11/13/20	Sheila Birnbaum	1.30	L120	A104	1,755.00		
	Review slide deck from UCC (1.3).						

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 21 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 8

<u> Dате</u>	TIMEKEEPER	Hours Task	<u>K</u>	<u>ACTIVITY</u>	AMOUNT		
11/13/20	Hayden Coleman	2.90	L120	A104	2,653.50		
	Review and analyze UCC PowerPoint presentation regarding possible fraudulent transfer claims and cited exhibits.						
11/13/20	Hayden Coleman	0.40	L120	A106	366.00		
	Conference with client and Dechert team reg	garding claim	ıs evalu	ation.			
11/13/20	Hayden Coleman	1.60	L120	A107	1,464.00		
	Conference call with Dechert and DPW regar related expert issues (0.5); plan for and parti Cornerstone and DPW regarding claims evalu	cipate in We					
11/13/20	Hayden Coleman	2.00	L120	A108	1,830.00		
	Plan for and participate in presentation from fraudulent transfer claims.	UCC regardi	ing pos	sible			
11/13/20	Mara Cusker Gonzalez	0.40	L120	A105	366.00		
	Confer with litigation team regarding legal revaluation and disclosure strategy regarding of						
11/13/20	Mara Cusker Gonzalez	0.80	L120	A107	732.00		
	Participate in video meetings with bankruptor and expert consultants regarding claims allow liquidation analysis regarding public, personal claimants (.8).	cation and es	stimatio	on and			
11/13/20	Mara Cusker Gonzalez	0.70	L120	A104	640.50		
	Review legal research regarding claims alloca (.7).	ation and est	imatior	n analysis			
11/13/20	Sara Roitman	2.00	L120	A107	1,830.00		
	Communicate with co-counsel and consultar	nts regarding	valuati	ion analysis.			
11/13/20	Sara Roitman	1.00	L120	A104	915.00		
	Analyze statute of limitations issues for third and strategy regarding same.	party payor	and ho	spital claims			
11/13/20	Sara Roitman	2.00	L120	A104	1,830.00		
	Review and analyze UCC's presentation on S of action.	ackler liabilit	y and e	state causes			
11/13/20	Jenna Newmark	0.80	L120	A104	684.00		
	Review and analyze memorandum on third p	arty payor cl	laims (0	0.8).			
11/13/20	Theodore Yale	3.40		A102	2,465.00		
	Research regarding statute of limitations (1.0 (2.4).	D); draft outli	ine rega	arding same			
11/13/20	Christopher Boisvert	1.00		A102	890.00		
	Legal research regarding statute of limitation by third party payor and hospital claimants.	ns issues rela	ted to	claims made			
11/13/20	Danielle Gentin Stock	2.20	L120	A104	1,958.00		
	Review and analyze UCC presentation deck.						

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 22 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 9

<u>Date</u>	Тімекеерег	Hours Tas	<u>sk</u>	<u>ACTIVITY</u>	AMOUNT
11/13/20	Danielle Gentin Stock	1.50	L120	A107	1,335.00
	Participate on calls with co-counsel regardin	g claims ana	alysis.		
11/13/20	Danielle Gentin Stock	0.40	L120	A105	356.00
	Confer internally regarding UCC presentation	n.			
11/13/20	Danielle Gentin Stock	0.50	L120	A105	445.00
	Correspond with client and internally regard	ling Monitor	's report.		
11/13/20	Danielle Gentin Stock	0.30	L120	A104	267.00
	Review Monitor findings.				
11/13/20	Danielle Gentin Stock	0.20	L120	A104	178.00
	Review correspondence regarding neonatal	abstinence s	syndrome	e motion.	
11/13/20	Danielle Gentin Stock	0.20	L120	A104	178.00
	Review and edit company statement relating	g to Monitor	findings	(.2).	
11/13/20	Danielle Gentin Stock	0.20	L120	A106	178.00
	Correspond with client regarding same comp Monitor findings (.2).	pany statem	ent relati	ng to	
11/13/20	Jonathan Tam	0.50	L120	A107	445.00
	Strategize and confer with co-counsel regard payor claims (0.5).	ding hospita	l and thire	d party	
11/14/20	Hayden Coleman	0.30	L120	A107	274.50
	Emails with DPW and Dechert team regarding Group Draft 2004 motion and supporting ex	_		= = = = = = = = = = = = = = = = = = = =	
11/14/20	Hayden Coleman	2.10	L120	A104	1,921.50
	Review and analyze neonatal abstinence synand supporting exhibits and declarations.	ıdrome Groเ	up Draft 2	004 motion	
11/15/20	Hayden Coleman	0.40	L120	A106	366.00
	Conferences and correspondence with client neonatal abstinence syndrome 2004 motion		rt team re	egarding	
11/15/20	Mara Cusker Gonzalez	2.00	L120	A103	1,830.00
	Review and draft response to fact-checking book publication regarding Purdue.	inquiry rega	rding fort	hcoming	
11/15/20	Jenna Newmark	0.30	L120	A104	256.50
	Review summary of motions for neonatal ab certification (0.3).	stinence syr	ndrome cl	lass	
11/15/20	Danielle Gentin Stock	1.50	L120	A104	1,335.00
	Research responses to client factual questio related to client questions (0.3).	ns (1.2); rev	iew corre	spondence	
11/16/20	Sheila Birnbaum	2.30	L120	A104	3,105.00
	Review filed monitors Third Report (0.8); revaluation abstinence syndrome claimants abatement pregarding bankruptcy (0.7).				

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 23 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 10

<u>Date</u>	Тімекеерег	Hours Tas	<u>sk</u>	ACTIVITY	AMOUNT
11/16/20	Sheila Birnbaum	0.30	L120	A106	405.00
	Telephone conference with Purdue, Reed Sm (0.3).	nith regardir	ng insura	nce issues	
11/16/20	Hayden Coleman	2.90	L120	A106	2,653.50
	Participate in WebEx with client and DPW re conference call with Dechert, DPW and clien syndrome Ad Hoc 2004 Motion (0.6); commuclient regarding same (0.7); communicate wiregarding responses to fact checking inquiry	t regarding unicate with th client an	neonata n Dechert d Decher	l abstinence c, DPW and	
11/16/20	Hayden Coleman	0.80	L120	A105	732.00
	Conference call with Dechert team regarding effectuating reorganization plan (0.5); comm regarding lain Cockburn (0.3).				
11/16/20	Hayden Coleman	1.90	L120	A104	1,738.50
	Review and respond to outline of task list for plan (1.1); review and comment on Multi-stasheet (0.8).				
11/16/20	Mara Cusker Gonzalez	1.80	L120	A103	1,647.00
	Draft and revise response to fact-checking in book publication regarding Purdue.	quiry regard	ding fortl	ncoming	
11/16/20	Sara Roitman	0.50	L120	A106	457.50
	Confer with client and insurance counsel reg negotiations.	arding insur	rance set	tlement	
11/16/20	Lindsay Zanello	0.10	L120	A107	80.00
	Communicate with local counsel regarding V	Vest Virginia	a cases.		
11/16/20	Christopher Boisvert	1.20	L120	A104	1,068.00
	Review outline of third party payor and hosp memorandum.	oital statute	of limita	tions	
11/16/20	Danielle Gentin Stock	0.60	L120	A104	534.00
	Review and edit summary of Monitor finding (0.5); review correspondence relating to ban	•	•	ith client	
11/16/20	Danielle Gentin Stock	2.20	L120	A105	1,958.00
	Confer and correspond internally regarding remotion and next steps in bankruptcy plan (2. gathering responses (0.2).			•	
11/16/20	Danielle Gentin Stock	1.40	L120	A107	1,246.00
	Confer with co-counsel regarding gathering in neonatal abstinence syndrome motion (0.7); counsel regarding the same (0.2); corresponding monitor report (0.2); confer with cabstinence syndrome motion (0.3).	correspond d with co-co	d with clicounsel an	ent and co- id client	

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 24 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 11

<u>Date</u>	TIMEKEEPER	Hours T	<u>ASK</u>	<u>ACTIVITY</u>	AMOUNT		
11/16/20	Jonathan Tam	0.50	L120	A102	445.00		
	Conduct research for, strategize regarding, and communicate in firm regarding claims and liquidation analysis (0.5).						
11/16/20	Jonathan Tam	0.80	L120	A104	712.00		
	Review and analyze analysis of personal inju	ry claims (0.8).				
11/17/20	Hayden Coleman	0.60	L120	A106	549.00		
	Conference and correspondence with client same.	and Deche	ert team r	egarding			
11/17/20	Mara Cusker Gonzalez	0.40	L120	A105	366.00		
	Confer with litigation counsel regarding lega	ıl analysis c	of comme	rcial claims.			
11/17/20	Sara Roitman	0.80	L120	A105	732.00		
	Communicate with Dechert team regarding	claims valu	uation stra	ategy.			
11/17/20	Danielle Gentin Stock	0.90	L120	A104	801.00		
	Update and circulate Monitor recommendat responses to media and correspond internal correspondence relating to neonatal abstine	lly regardin	ng same (0	0.2); review			
11/17/20	Paul LaFata	0.50	L120	A104	445.00		
	Analyze pleadings on discovery and privilege	e disputes a	and monit	tor report.			
11/18/20	Sheila Birnbaum	3.90	L120	A104	5,265.00		
	Review plan materials (0.7); review DOJ info	rmation fo	r accurac	y (0.8).			
11/18/20	Sheila Birnbaum	0.50	L120	A106	675.00		
	Telephone conference with Purdue regardin	g Congress	sional hea	ring (0.5).			
11/18/20	Hayden Coleman	1.50	L120	A104	1,372.50		
	Review and analyze House Bills regarding rereview and analyze Term Sheet of restructure (1.2).	-	=				
11/18/20	Hayden Coleman	0.60	L120	A108	549.00		
	Participate in conference call with Dechert a personal injury claims.	ınd D. Gree	enspan re	garding			
11/18/20	Hayden Coleman	0.50	L120	A106	457.50		
	Plan for and participate in conference call w Keefe fact checker questions (0.5).	ith client re	egarding ı	responses to			
11/18/20	Mara Cusker Gonzalez	1.50	L120	A103	1,372.50		
	Draft/revise response to fact-checking inqui publication regarding Purdue.	ry regardin	ng forthco	ming book			
11/18/20	Danielle Gentin Stock	1.10	L120	A105	979.00		
	Confer internally regarding personal injury a regarding status of negotiations (0.6).	nalysis (0.5	5); confer	internally			
11/18/20	Danielle Gentin Stock	0.40	L120	A104	356.00		
	Review correspondence regarding bankrupt correspond regarding media response (0.3).	-	(0.1); rev	iew and			

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 25 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 12

<u>Date</u>	Тімекеерег	Hours Tas	<u> </u>	ACTIVITY	AMOUNT
11/18/20	Danielle Gentin Stock	0.60	L120	A106	534.00
	Confer with client regarding responses to mouth client regarding Monitor inquiry (0.1).	edia inquiry	(0.5); co	rrespond	
11/19/20	Sheila Birnbaum	0.30	L120	A107	405.00
	Telephone conference with Purdue lawyers	regarding co	ongressio	onal hearing.	
11/19/20	Sheila Birnbaum	0.80	L120	A104	1,080.00
	Review information from DOJ (0.8).				
11/19/20	Sheila Birnbaum	1.50	L120	A108	2,025.00
	Telephone conference with staff of Congress with UCC regarding insurance issues (0.8); to Wilmer Hale regarding hearings (0.3).				
11/19/20	Sheila Birnbaum	4.00	L120	A109	5,400.00
	Attend Purdue Board of Directors Meeting.				
11/19/20	Hayden Coleman	1.00	L120	A106	915.00
	Participate in WebEx with DPW and client re	garding plar	n proces	s (1.0).	
11/19/20	Theodore Yale	1.90	L120	A102	1,377.50
	Research and draft memorandum regarding party payor and Hospital claims.	statute of li	mitation	s for third	
11/19/20	Jonathan Tam	0.30	L120	A105	267.00
	Communicate in firm regarding abatement is	ssues (0.3).			
11/20/20	Sheila Birnbaum	0.50	L120	A105	675.00
	Telephone conference with Dechert team re	garding stat	us of pro	ojects.	
11/20/20	Hayden Coleman	0.80	L120	A104	732.00
	Review and analyze memorandum regarding party payor and Hospital claims (0.4); review regarding public side abatement models (0.4)	and respon			
11/20/20	Hayden Coleman	1.30	L120	A106	1,189.50
	Communicate with client and Dechert team	regarding Ke	eefe (1.3	s).	
11/20/20	Mara Cusker Gonzalez	2.00	L120	A108	1,830.00
	Prepare for and attend video meetings with counsel, and expert consultants regarding cl and liquidation analysis (1.5); review legal re	aims allocat	ion and	estimation	
11/20/20	Mara Cusker Gonzalez	0.60	L120	A103	549.00
	Review and revise research memorandum restrategy relating to commercial claims.	egarding valu	uation a	nd disclosure	
11/20/20	Sara Roitman	0.70	L120	A104	640.50
	Analyze issues regarding valuation of public, municipality claims.	Canada, pe	rsonal in	jury, and	
11/20/20	Theodore Yale	4.30	L120	A103	3,117.50
	Draft memorandum regarding statute of lim	itations issu	es (4.3).		

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 26 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 13

DATE	TIMEKEEPER	Hours Ta	<u>.SK</u>	ACTIVITY	<u>Amount</u>
11/20/20	Christopher Boisvert	1.50	L120	A103	1,335.00
	Review and revise memorandum regarding limitations issues.	third party p	oayor sta	tute of	
11/20/20	Christopher Boisvert	1.00	L120	A103	890.00
	Confidentiality review of Agreements betwee connection with Endo's production of same.		d Purdue	in	
11/23/20	Hayden Coleman	0.70	L120	A106	640.50
	Communicate with client and outside couns syndrome group's document request (.3); coregarding scheduling and logistics (.4).				
11/23/20	Hayden Coleman	0.60	L120	A104	549.00
	Review and comment on proposed response (.3); review media reports regarding expecte			er inquiries	
11/23/20	Christopher Boisvert	0.40	L120	A104	356.00
	Review Strickland (Texas state court) person	nal injury co	mplaint.		
11/23/20	Paul LaFata	0.50	L120	A103	445.00
	Draft revisions to regulatory submission (0.5	5).			
11/24/20	Sheila Birnbaum	2.10	L120	A107	2,835.00
	Review presentation for NAACP (0.8); review and representative of consenting states (0.5 (0.8).				
11/24/20	Sheila Birnbaum	0.60	L120	A107	810.00
	Attend Purdue weekly lawyer call regarding	case status	and litiga	ation.	
11/24/20	Hayden Coleman	0.60	L120	A107	549.00
	Communicate with Dechert and DPW regard lawsuit filed against Purdue (0.3); communic teams regarding neonatal abstinence syndrometric syndrometric communications.	cate with De	echert an	d DPW	
11/24/20	Hayden Coleman	0.90	L120	A106	823.50
	Plan for and participate in principals call wit counsel (0.5); communicate with client, DPV Canadian litigation (0.4).				
11/24/20	Christopher Boisvert	1.60	L120	A103	1,424.00
	Draft and revise Notice of Bankruptcy in Stri personal injury case.	ckland Texa	s state co	ourt	
11/24/20	Jonathan Tam	0.60	L120	A105	534.00
	Communicate in firm regarding neonatal abiliquidation analyses (0.6).	stinence syr	ndrome d	laims and	
11/25/20	Sheila Birnbaum	1.50	L120	A104	2,025.00
	Review slide deck regarding presentation to materials and documents (0.8).	NAACP (0.7	'); review	C. Landau	

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 27 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 14

<u>Date</u>	Тімекеерек	Hours Ta	<u>SK</u>	<u>ACTIVITY</u>	AMOUNT
11/25/20	Hayden Coleman	4.30	L120	A107	3,934.50
	Attend WebEx with Dechert, DPW, and Coranalysis (1.0); communicate with Dechert to regarding authentication of Purdue docume claimants' counsel and DPW regarding term conferences to/from Dechert and Wilmer reCongressional hearings (2.0).	eam and plai ents (0.5); co n sheets (0.8)	ntiffs' co mmunic); emails	ounsel ate with and	
11/25/20	Hayden Coleman	2.80	L120	A104	2,562.00
	Review reports regarding potential fraudule activity (0.8); review and compile materials Congressional hearings (2.0).			_	
11/25/20	Danielle Gentin Stock	0.80	L120	A105	712.00
	Correspond internally regarding document internally regarding potential Congressiona			confer	
11/25/20	Danielle Gentin Stock	2.10	L120	A107	1,869.00
	Correspond with co-counsel and internally hearing (0.8); participate on call with co-couloid claims analysis (1.3).			_	
11/25/20	Paul LaFata	0.30	L120	A105	267.00
	Confer with counsel regarding document co	ertification re	esearch a	and analysis.	
11/27/20	Danielle Gentin Stock	0.10	L120	A105	89.00
	Confer internally regarding Monitor's repor	ts.			
11/28/20	Mara Cusker Gonzalez	0.60	L120	A104	549.00
	Review media reports regarding product sa with litigation team regarding response to s litigation work product (0.2).			•	
11/28/20	Danielle Gentin Stock	1.50	L120	A107	1,335.00
	Correspond internally and with co-counsel hearing (0.2); correspond internally and wit Times article and review the same (1.3).			_	
11/28/20	Danielle Gentin Stock	1.00	L120	A105	890.00
	Confer internally regarding case developme	ents (1.0).			
11/28/20	Paul LaFata	0.30	L120	A104	267.00
	Analyze media material on case documents	(0.3).			
11/28/20	Paul LaFata	0.90	L120	A107	801.00
	Confer with counsel (0.3) and non-party coudocuments.	unsel (0.6) m	aterials/	'case	
11/29/20	Sara Roitman	1.00	L120	A104	915.00
	Draft summary of MDL and related litigation preparation.	n for congres	ssional te	estimony	
11/29/20	Sara Roitman	0.60	L120	A105	549.00
	Communicate with Dechert team regarding	Congression	nal heari	ngs.	

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 28 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 15

DATE	TIMEKEEPER	Hours Tasi	ĸ	ACTIVITY	Amount
<u> </u>	Danielle Gentin Stock	0.90	_	A105	801.00
	Correspond internally regarding gathering is Congressional hearing (0.4); confer internation for potential Congressional hearing	lly regarding g	-		
11/29/20	Danielle Gentin Stock	0.20	L120	A107	178.00
	Correspond with co-counsel regarding pote	ential Congress	sional h	earing.	
11/30/20	Sheila Birnbaum	1.50	L120	A104	2,025.00
	Review Public Health Initiative presentation agreement for insurers and emails regarding		confide	entiality	
11/30/20	Sheila Birnbaum	0.50	L120	A107	675.00
	Telephone conference with Purdue lawyers (0.5).	regarding Co	ngressio	onal hearing	
11/30/20	Sara Roitman	1.50	L120	A104	1,372.50
	Analyze congressional hearing presentation talking points regarding same (.7).	n (.8); review a	nd revi	se proposed	
11/30/20	Danielle Gentin Stock	0.10	L120	A104	89.00
	Review and comment on potential Congress requests for information (0.6).	sional informa	ation de	eck and	
11/30/20	Danielle Gentin Stock	0.30	L120	A105	267.00
	Confer internally regarding potential Congr	essional heari	ng.		
11/30/20	Danielle Gentin Stock	0.70	L120	A107	623.00
	Correspond with co-counsel regarding Mor	nitor recomme	ndation	ns (0.7).	
11/30/20	Danielle Gentin Stock	2.00	L120	A106	1,780.00
	Correspond and confer with client regarding	g market acce	ss quer	ies (2.0).	
11/30/20	Jonathan Tam	0.90	L120	A107	801.00
	Communicate in firm and with co-counsel r	egarding clain	ns analy	/sis (0.4).	
11/30/20	Antonella Capobianco-Ranallo	0.50	L120	A102	100.00
	Assist J. Newmark with WV neonatal abstin	ence syndrom	ne claim	s research.	
L120 SUBTO	AL HOURS AND FEES:	212.30			205,964.50
I 130 - Evner	:s/Consultants				
11/04/20	Jenna Newmark	0.10	1130	A107	85.50
11/04/20	Draft email correspondence regarding prior Cornerstone (0.1).				03.30
11/05/20	Hayden Coleman	0.60	L130	A105	549.00
	Conference call with Dechert team regardine expert work (0.6).	ng claims evalu	uation a	and related	
11/05/20	Sara Roitman	1.30	L130	A104	1,189.50
	Review and analyze experts for neonatal abregarding analysis (1.3).	ostinence synd	lrome c	laimants	

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 29 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 16

DATE	TIMEKEEPER	Hours Task	<u> </u>	ACTIVITY	AMOUNT
11/06/20	Sheila Birnbaum	0.50	L130	A107	675.00
	Discussion between Davis Polk and Dechert	regarding exp	ert.		
11/06/20	Jenna Newmark	2.50	L130	A107	2,137.50
	Participate in videoconference with Davis Po for call with Cornerstone regarding claims as videoconference with Davis Polk and Corner analysis (1.3); review email correspondence	nalysis (0.8); p stone team r	particip egardin	ate in ng claims	
11/06/20	Jonathan Tam	1.30	L130	A108	1,157.00
	Strategize and confer with experts regarding	g estimation a	analysis	(1.3).	
11/11/20	Jenna Newmark	0.20	L130	A104	171.00
	Review Cornerstone email regarding hospita	al claims analy	ysis (0.2	2).	
11/12/20	Sara Roitman	1.50	L130	A107	1,372.50
	Confer with consultants regarding personal	injury claims	valuatio	on.	
11/12/20	Jenna Newmark	1.50	L130	A107	1,282.50
	Participate in videoconference with expert E team (1.2); review email correspondence reclaims (0.3).	•			
11/13/20	Jenna Newmark	1.70	L130	A107	1,453.50
	Participate in videoconference with Davis Po Cornerstone team (0.6); participate in video team regarding valuation analysis (1.1).	· · · · · · · · · · · · · · · · · · ·	-		
11/13/20	Jonathan Tam	1.10	L130	A108	979.00
	Strategize and confer with experts regarding (1.1) .	g claims and li	iquidati	on analysis	
11/16/20	Hope Freiwald	0.30	L130	A106	327.00
	Communicate with client regarding potentia	ıl economist e	expert (.3).	
11/16/20	Sara Roitman	2.00	L130	A107	1,830.00
	Communicate with consultants regarding th analysis.	e personal inj	jury val	uation	
11/17/20	Jenna Newmark	0.40	L130	A107	342.00
	Participate in videoconference with Brattle a analysis of public claims (0.4)	and Cornersto	one reg	arding	
11/18/20	Sara Roitman	1.80	L130	A107	1,647.00
	Confer with consultants regarding claim valu	uation.			
11/18/20	Jenna Newmark	1.30	L130	A108	1,111.50
	Review and analyze Cornerstone materials s settlements (0.7); participate in telephone c regarding personal injury claims analysis (0.6)	all with exper	-		
11/19/20	Jenna Newmark	3.80	L130	A104	3,249.00
	Review prior expert reports and medical lite period (2.8); draft email memorandum rega period (1.0).				

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Filed 02/11/21 Entered 02/11/21 12:25:06 Pg 30 of 92

Main Document

Invoice 1010003211 Page 17

<u>Date</u>	TIMEKEEPER	Hours Task		ACTIVITY	AMOUNT
11/20/20	Sara Roitman	2.50	L130	A107	2,287.50
	Confer with bankruptcy counsel and experts personal injury, public claimant, and comme				
11/20/20	Jenna Newmark	3.40	L130	A107	2,907.00
	Participate in videoconference with Davis Po Cornerstone team (1.0); participate in videoc team regarding valuation analysis (1.4); draft regarding abatement period for Cornerstone	conference wi t/revise email	th Cor memo	nerstone	
11/20/20	Jonathan Tam	1.00	L130	A107	890.00
	Strategize and confer with co-counsel regard (1.0).	ling expert an	alysis (of claims	
11/20/20	Jonathan Tam	1.20	L130	A108	1,068.00
	Strategize and confer with experts regarding	analysis of cl	aims (1	L.O).	
11/23/20	Mara Cusker Gonzalez	0.30	L130	A104	274.50
	Review New York expert reports and analysis claims analysis and valuation and disclosure litigation counsel regarding same (0.1).			-	
11/23/20	Jenna Newmark	0.60	L130	A104	513.00
	Review correspondence regarding additional	l classes for cl	aims a	nalysis (0.6).	
11/23/20	Jonathan Tam	0.20	L130	A105	178.00
	Communicate in firm regarding confidentialidepositions (0.2, WA & CA).	ty issues rega	rding e	expert	
11/23/20	Jonathan Tam	0.20	L130	A105	178.00
	Communicate in firm regarding plaintiffs' exp	oert reports (0).2, CA).	
11/24/20	Sara Roitman	0.50	L130	A104	457.50
	Review and analyze issues regarding request in state court litigation.	from co-Defe	endant	s for expert	
11/24/20	Jenna Newmark	0.40	L130	A109	342.00
	Participate in videoconference with Cornerst exchange of data (0.4).	one and Brat	tle tea	ms regarding	
11/24/20	Jonathan Tam	0.20	L130	A105	178.00
	Communicate in firm regarding confidentiality expert depositions (0.2, WA & CA).	ty issues in co	nnecti	on with	
11/25/20	Sara Roitman	1.10	L130	A107	1,006.50
	Confer with consultants regarding public, pri valuation analysis.	vate, and con	nmerci	al claimant	
L130 SUBTOTA	AL HOURS AND FEES:	33.50			29,838.50
L140 – Docum	ent/File Management				

L140 – Docu	ment/File Management			
11/09/20	Antonella Capobianco-Ranallo	1.00	L140 A111	200.00
	Gather new filings and distribute to team leaders.			

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 31 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 18

DATE	TIMEKEEPER	Hours Tas	<u>sk</u>	ACTIVITY	AMOUNT
11/24/20	Antonella Capobianco-Ranallo	0.50	L140	A111	100.00
	Gather new filings and distribute to tear	n leaders.			
11/25/20	Antonella Capobianco-Ranallo	0.50	L140	A111	100.00
	Gather new filings and distribute to tear	n leaders.			
11/30/20	Antonella Capobianco-Ranallo	0.50	L140	A111	100.00
	Gather new filings and distribute to tear	n leaders.			
L140 SUBTOT	AL HOURS AND FEES:	2.50			500.00
L150 – Budge	ting				
11/23/20	Hayden Coleman	1.40	L150	A106	1,281.00
	Prepare for and participate in conference for 2021 and related issues.	e call with client	t regardii	ng budgets	
L150 SUBTOT	AL HOURS AND FEES:	1.40			1,281.00
L160 – Settle	ment/Non-Binding ADR				
11/02/20	Sheila Birnbaum	1.00	L160	A108	1,350.00
	Telephone conference with representati settlement issues.	ive of consenting	g states r	egarding	
11/02/20	Sheila Birnbaum	0.90	L160	A106	1,215.00
	Telephone conference with Purdue rega conference with M. Kesselman regarding		•	•	
11/02/20	Sheila Birnbaum	0.50	L160	A107	675.00
	Telephone conference with mediator re	garding settleme	ent issue	S.	
11/02/20	Sara Roitman	0.60	L160	A105	549.00
	Communicate with Dechert team regard	ling settlement i	ssues.		
11/03/20	Sheila Birnbaum	3.80	L160	A108	5,130.00
	Telephone conference with mediator reputer.	garding settleme	ent issue	s raised by	
11/03/20	Sheila Birnbaum	0.30	L160	A106	405.00
	Telephone conference with M. Kesselma settlement issues (0.3).	an and M. Heubi	ner regar	ding	
11/03/20	Hayden Coleman	0.80	L160	A105	732.00
	Conference calls with Dechert team regardless (0.8).	arding mediation	n update	s and	
11/03/20	Hayden Coleman	0.30	L160	A106	274.50
	Communicate with client and retained c settlement (0.3).	ounsel regarding	g distribu	utor	
11/03/20	Hayden Coleman	2.20	L160	A106	2,013.00
	Communicate with client and retained c settlement with UCC and non-consentin			e dispute	

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 32 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 19

<u>Date</u>	TIMEKEEPER	Hours Tas	<u>K</u>	ACTIVITY	AMOUNT
11/03/20	Hayden Coleman	0.30	L160	A104	274.50
	Review and analyze reports on distributor se	ettlement (0.	3).		
11/04/20	Sheila Birnbaum	0.90	L160	A106	1,215.00
	Telephone conference with M. Kesselman re telephone conference with R. Silbert regardi				
11/04/20	Sheila Birnbaum	0.50	L160	A107	675.00
	Telephone conference with mediator regard	ling settleme	nt issue	es.	
11/04/20	Hayden Coleman	1.10	L160	A104	1,006.50
	Review and analyze reports and emails regardefendants' settlements (0.7); draft reports ramifications of election on FDA and opioid	to client rega	arding p	-	
11/04/20	Sara Roitman	1.50	L160	A104	1,372.50
	Analyze distributor settlement and implication (.6); draft analysis regarding same (.9).	ons for Purdi	ue regai	rding same	
11/04/20	Sara Roitman	0.80	L160	A105	732.00
	Communicate with Dechert team regarding	settlement s	trategy.		
11/04/20	Danielle Gentin Stock	0.10	L160	A104	89.00
	Review opioid settlement correspondence.				
11/05/20	Sheila Birnbaum	1.60	L160	A107	2,160.00
	Telephone conference with Davis Polk regar telephone conference with Davis Polk regard telephone conference with distribution lawy settlement (0.7).	ding settleme	ent issue	es (0.4);	
11/05/20	Sheila Birnbaum	1.50	L160	A106	2,025.00
	Telephone conference with R. Silbert and S. issues (0.5); telephone conference with Purcregarding status of litigation (0.5); telephone Rothman regarding settlement issues (0.5).	due and disco	overy la	wyers	
11/05/20	Sheila Birnbaum	0.80	L160	A108	1,080.00
	Telephone conference with representative c settlement issues (0.8).	of consenting	states	regarding	
11/05/20	Sara Roitman	0.70	L160	A106	640.50
	Communicate with client regarding settleme initiatives (.4).	ent (.3) and p	ublic he	ealth	
11/05/20	Danielle Gentin Stock	0.60	L160	A105	534.00
	Confer internally regarding settlement (0.6).				
11/06/20	Sheila Birnbaum	1.00	L160	A108	1,350.00
	Telephone conference with L. Strange, T. Ba (1.0).	ker et al. reg	arding s	ettlement	
11/06/20	Hayden Coleman	0.40	L160	A104	366.00
	Review and analyze reports on J&J and Distr	ibutor settle	ments (0.4).	

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 33 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 20

<u>Date</u>	TIMEKEEPER	Hours Tas	<u> Астіліту</u>	Amount
11/06/20	Sara Roitman	1.00	L160 A104	915.00
	Review and analyze deposition summaries f settlement implications.	or S. Baker a	nd K. Sackler for	
11/06/20	Sara Roitman	0.70	L160 A105	640.50
	Communicate with Dechert team regarding	settlement s	strategy.	
11/09/20	Sheila Birnbaum	0.30	L160 A107	405.00
	Telephone conference with mediator regard	ding settleme	ent (0.3)	
11/09/20	Sara Roitman	0.70	L160 A105	640.50
	Communicate with Dechert team regarding strategy.	mediation a	nd settlement	
11/10/20	Sheila Birnbaum	0.30	L160 A105	405.00
	Telephone conference with H. Coleman reg	arding settle	ment issues.	
11/10/20	Sheila Birnbaum	1.00	L160 A107	1,350.00
	Telephone conference with Purdue team of settlement.	lawyers rega	arding status of	
11/10/20	Sheila Birnbaum	2.60	L160 A108	3,510.00
	Telephone conference with representative of settlement (0.8); telephone conference with consenting states regarding settlement (0.8 mediators regarding settlement (0.5); telephone representatives of non-consenting states re	n Ad Hoc con); telephone hone confere	nmittee of conference with ence with	
11/10/20	Sheila Birnbaum	1.20	L160 A106	1,620.00
	Telephone conferences with M. Kesselman settlement issue (1.2).	and M. Hueb	oner regarding	
11/10/20	Hayden Coleman	0.80	L160 A104	732.00
	Review and analyze letters from House Rep Department of Justice regarding DOJ settler		and Senators to	
11/10/20	Hayden Coleman	1.20	L160 A106	1,098.00
	Conference and correspondence with Dech ramifications of letters from House Represe Department of Justice regarding DOJ settler	ntatives and	Senators to	
11/10/20	Sara Roitman	1.50	L160 A104	1,372.50
	Review and analyze objections to DOJ settle	ement.		
11/10/20	Sara Roitman	0.50	L160 A103	457.50
	Draft summary regarding recent developme settlement regarding same.	ents in MDL a	and implications for	
11/10/20	Danielle Gentin Stock	0.50	L160 A104	445.00
	Review objections to motion to approve DC from Senators to DOJ regarding settlement		(0.2); review letter	
11/10/20	Danielle Gentin Stock	0.40	L160 A107	356.00
	Correspond internally, with client, and co-co (0.4).	ounsel regard	ding DOJ settlement	

Filed 02/11/21 Entered 02/11/21 12:25:06 Pg 34 of 92 Main Document

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211

Page 21

<u>Date</u>	TIMEKEEPER	Hours Tas	<u>K</u>	ACTIVITY	Amount
11/11/20	Sheila Birnbaum	2.80	L160	A108	3,780.00
	Telephone conference with mediator regard conference with monitor regarding settlement with mediator regarding settlement issues (I representative of consenting states regarding conference with mediator regarding settlement issues as	ent (0.4); tele 0.8); telepho ig settlement ient (0.4); tel	ephone one confo t (0.5); t lephone	conference erence with elephone conference	
11/11/20	Sheila Birnbaum	2.00	L160	A106	2,700.00
	Telephone conference with R. Silbert regard presentation (0.5); multiple telephone confe M. Huebner regarding settlement issues (1.0 Purdue regarding mediator's recommendati	erences with 0); telephone	M. Kess	elman and	
11/11/20	Sheila Birnbaum	0.80	L160	A104	1,080.00
	Review filings regarding approval of DOJ set	tlement (0.8)).		
11/11/20	Hayden Coleman	0.60	L160	A106	549.00
	Communicate with client and outside counse settlement.	el regarding	objectio	ons to DOJ	
11/11/20	Hayden Coleman	0.50	L160	A105	457.50
	Conference call with Dechert team regarding Senators in connection to settlement.	g responses t	to letter	s from	
11/11/20	Hayden Coleman	0.60	L160	A104	549.00
	Review and analyze reports regarding emplo critiques of DOJ settlement (0.6).	yee retentio	n struct	cure and	
11/11/20	Sara Roitman	1.00	L160	A104	915.00
	Review and analyze creditors' letters to DOJ	regarding Pu	urdue se	ettlement.	
11/11/20	Sara Roitman	1.40	L160	A104	1,281.00
	Review and analyze various creditor objection	ons for DOJ s	ettleme	nt approval.	
11/11/20	Danielle Gentin Stock	0.50		A105	445.00
	Confer internally regarding objections to DO				
11/11/20	Danielle Gentin Stock	0.40		A104	356.00
	Review correspondence related to plea agre				
11/12/20	Sheila Birnbaum	0.80		A108	1,080.00
44 /42 /20	Telephone conference with mediators regar	_		A40C	1 (20 00
11/12/20	Sheila Birnbaum Multiple telephone conferences with M. Kes regarding settlement issues.	1.20 sselman and		A106 oner	1,620.00
11/12/20	Hayden Coleman	0.40	L160	A104	366.00
,, -	Review objections to DOJ settlement (0.4).				223.30
11/12/20	Sara Roitman	1.90	L160	A105	1,738.50
	Communicate with Dechert team regarding party payors, hospitals, and neonatal abstine	claimant ana	ılysis reg	garding third	,

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 35 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 22

DATE	TIMEKEEPER	Hours TA	ASK	ACTIVITY	AMOUNT
 11/12/20	Danielle Gentin Stock	0.40		A105	356.00
	Confer internally regarding mediation.				
11/13/20	Sheila Birnbaum	0.30	L160	A106	405.00
	Telephone conference with M. Kesselman re	egarding set	ttlement.		
11/13/20	Sheila Birnbaum	2.90	L160	A108	3,915.00
	Multiple telephone conferences with media telephone conference with mediators regar conference with representative of consenting meeting between UCC and Debtors Advisors	ding settlen ng states (0.	nent (0.3) .3); media	; telephone ation	
11/13/20	Sheila Birnbaum	1.50	L160	A104	2,025.00
	Review response to 9019 motion (1.2); review	ew DOJ lette	er file (0.3	3).	
11/13/20	Sara Roitman	1.50	L160	A107	1,372.50
	Communicate with creditors and co-defend related issues regarding hospital claimants' the West Virginia litigation.				
11/13/20	Sara Roitman	1.60	L160	A105	1,464.00
	Communicate with Dechert team regarding strategy (0.7); communicate with Dechert to negotiations and Sackler settlement (0.9).				
11/15/20	Hayden Coleman	1.80	L160	A104	1,647.00
	Review and revise Debtors' Reply in support	t of DOJ sett	tlement.		
11/15/20	Sara Roitman	1.00	L160	A103	915.00
	Review and revise reply in support of motio	n to approv	e DOJ set	tlement.	
11/15/20	Sara Roitman	0.50	L160	A105	457.50
	Communicate with Dechert team regarding approve DOJ settlement.	reply in sup	port of m	notion to	
11/16/20	Sheila Birnbaum	1.20	L160	A108	1,620.00
	Telephone conference with representatives settlement issues (0.5); telephone conferen neonatal abstinence syndrome babies regar conference with mediator regarding settlem	ce with repo	resentativ ment (0.4)	ve of	
11/16/20	Sheila Birnbaum	2.70	L160	A106	3,645.00
	Telephone conference with M. Kesselman retelephone conference with Purdue regarding telephone conference with Purdue and Dav bankruptcy issues (1.0); Purdue meeting regissues (0.5).	g Public Hea is Polk rega	alth Initia rding sett	tive (0.6); lement and	
11/16/20	Sheila Birnbaum	0.30	L160	A104	405.00
	Review and response to emails regarding se	ttlement iss	sues (0.3)		
11/16/20	Hayden Coleman	2.20	L160	A104	2,013.00
	Review and revise Debtors' Reply in support	t of DOJ sett	tlement (2.2).	

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 36 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 23

DATE	TIMEKEEPER	Hours Tas	<u>K</u>	<u>ACTIVITY</u>	Amount
11/16/20	Sara Roitman	2.40	L160	A105	2,196.00
	Communicate with Dechert team regarding (1.6) and DOJ settlement and hearing (0.8).	liquidation a	nalysis	and strategy	
11/16/20	Sara Roitman	1.00	L160	A104	915.00
	Analyze issues relating to fact checking issue	in connection	on with	settlement.	
11/17/20	Sheila Birnbaum	0.40	L160	A106	540.00
	Telephone conferences with M. Kesselman r	egarding set	tlemen	t.	
11/17/20	Sheila Birnbaum	0.30	L160	A108	405.00
	Telephone with mediator regarding settleme	ent.			
11/17/20	Sara Roitman	0.70	L160	A104	640.50
	Review and revise fact checking responses.				
11/17/20	Sara Roitman	0.70	L160	A105	640.50
	Communicate with Dechert team regarding strategy.	settlement a	nd med	liation	
11/18/20	Sheila Birnbaum	0.80	L160	A107	1,080.00
	Telephone conference with T. Baker and Pur settlement (0.8); review public health initiat (1.0); review draft slides of public health init	ive presentat	_	_	
11/18/20	Sheila Birnbaum	0.30	L160	A105	405.00
	Telephone conference with Dechert lawyers settlement.	regarding pr	rojects f	for	
11/18/20	Sheila Birnbaum	0.60	L160	A106	810.00
	Telephone conference with M. Kesselman as settlement (0.3); telephone conference with (0.3).		_	_	
11/18/20	Sheila Birnbaum	1.50	L160	A108	2,025.00
	Telephone conference with monitors regard conference with mediators regarding settler	_	nt (1.0)	; telephone	
11/18/20	Hayden Coleman	0.30	L160	A105	274.50
	Conference call with Dechert team regarding	g mediation.			
11/18/20	Hayden Coleman	1.20	L160	A104	1,098.00
	Review critiques of ruling on DOJ settlement	t (1.2).			
11/18/20	Sara Roitman	1.00	L160	A106	915.00
	Confer with client and insurance counsel reg settlement negotiations.	garding strate	egy for i	nsurance	
11/18/20	Sara Roitman	2.60	L160	A105	2,379.00
	Communicate with Dechert team regarding settlement.	DOJ settleme	ent, Sac	kler	
11/18/20	Sara Roitman	1.80	L160	A104	1,647.00
	Analyze UCC and consenting states' presentates.	ations to the	Mediat	ors and	

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 37 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 24

DATE	TIMEKEEPER	Hours Tas	<u>sk</u>	ACTIVITY	AMOUNT
11/19/20	Sheila Birnbaum	0.30	L160	A106	405.00
	Telephone conference with M. Kesselman a settlement issues.	nd M. Huebr	ner rega	rding	
11/19/20	Sheila Birnbaum	0.40	L160	A105	540.00
	Telephone conference with Dechert team re	egarding pro	jects for	settlement.	
11/19/20	Sheila Birnbaum	0.60	L160	A108	810.00
	Telephone conferences with mediators rega	rding settler	ment (0.	6)	
11/19/20	Hayden Coleman	1.70	L160	A104	1,555.50
	Review and analyze W. Tong (AG of CT) segr settlement (0.2); review and comment on D		_	_	
11/19/20	Hayden Coleman	0.10	L160	A106	91.50
	Communicate with client and DPW regardin segment on WNPR regarding DOJ settlement		o W. To	ng (AG of CT)	
11/19/20	Sara Roitman	2.00	L160	A104	1,830.00
	Review and revise draft DOJ plea agreemen	t.			
11/19/20	Sara Roitman	2.30	L160	A105	2,104.50
	Communicate with Dechert team regarding mediation.	DOJ settlem	ent and	Sackler	
11/19/20	Sara Roitman	1.40	L160	A107	1,281.00
	Confer with creditors and insurance counse settlement negotiations and follow-up regard		trategy f	for insurance	
11/19/20	Danielle Gentin Stock	0.50	L160	A104	445.00
	Review DOJ plea agreement.				
11/19/20	Danielle Gentin Stock	0.20	L160	A107	178.00
	Correspond internally and with co-counsel r	egarding DO)J plea ag	greement.	
11/20/20	Sheila Birnbaum	1.50	L160	A103	2,025.00
	Review and revise presentation slides for Pu	ıblic Health I	nitiative		
11/20/20	Sheila Birnbaum	2.60	L160	A108	3,510.00
	Telephone conference with representative of settlement issues (0.8); telephone conferent committee regarding settlement issues (1.3) representative of Ad Hoc Committee regard	ce with Ad H); telephone	loc conso confere	enting nce with	
11/20/20	Sheila Birnbaum	2.10	L160	A106	2,835.00
	Telephone conference with Purdue regardir telephone conference with M. Kesselman re telephone conference with R. Silbert regard telephone conference with Purdue regardin	egarding sett ing Public He	lement i ealth Init	issues (0.5); tiative (0.3);	
11/20/20	Sara Roitman	0.80	L160	A104	732.00
	Analyze issues regarding public abatement t purposes.	erm period	for settle	ement	

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 38 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 25

<u>Date</u>	Тімекеереп	Hours Tas	<u>K</u>	<u>ACTIVITY</u>	AMOUNT	
11/23/20	Sheila Birnbaum	1.70	 L160	A106	2,295.00	
	Multiple telephone conferences with R. Silbe telephone conference with M. Kesselman re telephone conference with Purdue regarding	garding sett	lement	(0.4);		
11/23/20	Sheila Birnbaum	2.80	L160	A108	3,780.00	
	Telephone conference with representatives (0.8); multiple telephone conferences with n (0.5); telephone conference with Congressio regarding settlement (0.8); telephone conference with conference with Congression regarding settlement (0.8); telephone conference with Congression regarding settlement (0.8); telephone conference with representatives (0.7).	mediators reg onal Committ	garding tee repr	settlement esentative		
11/23/20	Sheila Birnbaum	1.30	L160	A104	1,755.00	
	Review DOJ plea agreement (0.8); review set Health Initiative (0.5).	ttlement issu	ues rega	rding Public		
11/23/20	Sara Roitman	1.00	L160	A104	915.00	
	Review DOJ guilty plea documents and relate	ed filings.				
11/23/20	Sara Roitman	1.00	L160	A107	915.00	
	Communicate with bankruptcy counsel rega and communications with claimant groups.	rding plan co	onfirma	tion strategy		
11/23/20	Sara Roitman	1.50	L160	A105	1,372.50	
	Communicate with Dechert team regarding valuation analysis.	plan confirm	ation p	roposal and		
11/23/20	Sara Roitman	0.50	L160	A104	457.50	
	Analyze issues regarding consenting states's	settlement p	osition.			
11/23/20	Danielle Gentin Stock	0.20	L160	A104	178.00	
	Review DOJ plea agreement materials.					
11/23/20	Danielle Gentin Stock	0.10	L160	A105	89.00	
	Correspond internally regarding settlement.					
11/24/20	Sheila Birnbaum	1.80		A108	2,430.00	
	Telephone conference with mediator regarding settlement (0.4); telephone conference with Reg Brown etc. regarding Congressional hearing (0.3); telephone conference with representative of Ad Hoc consenting states regarding settlement (0.8); telephone conference with J. Rice regarding settlement issues (0.3).					
11/24/20	Sheila Birnbaum	0.90	L160	A106	1,215.00	
	Telephone conference with M. Kesselman re telephone conference with R. Silbert regardi	-				
11/24/20	Hayden Coleman	0.30	L160	A104	274.50	
	Review and fact check media reports regard	ing plea hea	ring (0.3	3).		
11/24/20	Hayden Coleman	0.70	L160	A106	640.50	
	Correspond with Dechert and client regarding	ng Purdue ple	ea heari	ng (0.7).		

Filed 02/11/21 Entered 02/11/21 12:25:06 Pg 39 of 92 Main Document

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211

Page 26

DATE	Тімекеерег	Hours Tasi	<u> </u>	<u>ACTIVITY</u>	AMOUNT
11/24/20	Sara Roitman	0.80	L160	A106	732.00
	Communicate with client regarding Canadia implications for litigation regarding same.	n litigation ar	nd settle	ement and	
11/24/20	Sara Roitman	0.80	L160	A107	732.00
	Confer with neonatal abstinence syndrome counsel regarding settlement negotiations.	claimants and	d bankr	uptcy co-	
11/24/20	Sara Roitman	0.80	L160	A104	732.00
	Analyze issues regarding public and private settlement strategy.	claimant valu	ation a	nd	
11/24/20	Sara Roitman	1.40	L160	A105	1,281.00
	Communicate with Dechert team regarding valuation and settlement strategy.	public and pr	ivate cl	aimant	
11/24/20	Sara Roitman	0.60	L160	A107	549.00
	Communicate with bankruptcy and claiman settlement negotiations.	t counsel rega	arding i	nsurance	
11/24/20	Sara Roitman	0.60	L160	A104	549.00
	Analyze issues regarding West Virginia neor for settlement.	atal abstinen	ce sync	lrome claims	
11/25/20	Sheila Birnbaum	4.60	L160	A108	6,210.00
	Telephone conference with NAACP represer (1.0); telephone conference with mediators telephone conference with representatives (1.0); telephone conference with representatives (0.5); telephone conference with representatives regarding settlement issues (0.8).	regarding set of NAACP reg ative of Ad Ho	ttlemer garding oc conse	nt (1.3); settlement enting states	
11/25/20	Sheila Birnbaum	1.80	L160	A106	2,430.00
	Telephone conference with R. Silbert regard telephone conference with M. Kesselman retelephone conference with T. Baker and M. (0.8).	egarding settle	ement	(0.5);	
11/25/20	Sheila Birnbaum	0.30	L160	A104	405.00
	Review settlement demand (0.3).				
11/25/20	Sara Roitman	1.50	L160	A105	1,372.50
	Communicate with Dechert team regarding regarding depositions, claim valuations and		-		
11/30/20	Sheila Birnbaum	1.70	L160	A108	2,295.00
	Telephone conference with States and UCC (1.3); telephone conference with mediator in				
11/30/20	Sheila Birnbaum	1.40	L160	A106	1,890.00
	Telephone conference with M. Kesselman a settlement issues (0.4); telephone conferent Health Initiative (0.5); telephone conference presentation of Public Health Initiative (0.5)	ce with R. Silb with Purdue	ert reg	arding Public	

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 40 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 27

<u>Date</u>	Тімекеерег	Hours TA	isk Ac	CTIVITY	AMOUNT
11/30/20	Sheila Birnbaum	0.30	L160 A1	107	405.00
	Telephone conference with Davis Polk regar	ding settlen	nent issues ((0.3).	
11/30/20	Sara Roitman	3.00	L160 A1	104	2,745.00
	Analyze commercial, private, and public clai	mant valuat	tions.		
11/30/20	Sara Roitman	2.50	L160 A1	105	2,287.50
	Communicate with Dechert team regarding Sacklers and claimants, congressional hearing analysis.		_		
11/30/20	Danielle Gentin Stock	0.10	L160 A1	106	89.00
	Correspond with client regarding Public Hea	ا Ith Benefit	presentation	n (0.1).	
L160 SUBTOT	AL HOURS AND FEES:	135.80			152,301.50
L190 – Other	Case Assessment, Development and Adminis	tration			
11/02/20	Alyssa Clark	0.60	L190 A1	104	435.00
	Review co-defendant emails and filings regatrial (0.6, NY).	rding prepa	ration for up	ocoming	
11/19/20	Sara Roitman	0.30	L190 A1	107	274.50
	Communicate with co-counsel and Dechert Hill matter.	team regard	ding litigation	n cases in	
11/23/20	Alyssa Clark	2.40	L190 A1	104	1,740.00
	Review plaintiff expert reports for informati (2.4, NY).	on regardin	g alleged da	mages	
L190 SUBTOT	AL HOURS AND FEES:	3.30			2,449.50
L210 – Pleadi	ngs				
11/02/20	Hayden Coleman	0.70	L210 A1	104	640.50
	Review and analyze S. Baker request for an a response, and Judge Drain's ruling (0.7).	adjournmen	nt, the UCC's		
11/02/20	Danielle Gentin Stock	1.30	L210 A1	104	1,157.00
	Review proposed resolution of privileged do correspondence regarding the same (0.5).	cument dis	pute (0.8); r	eview	
11/02/20	Danielle Gentin Stock	0.70	L210 A1	105	623.00
	Confer internally regarding proposed resolution dispute (0.7).	tion of privi	leged docun	nent	
11/03/20	Danielle Gentin Stock	0.50	L210 A1	104	445.00
	Review emails concerning dispute over privi correspondence regarding Monitor producti response to privileged document proposal (ions and rep	, ,,		
11/04/20	Sara Roitman	0.80	L210 A1	104	732.00
	Review and revise insurance complaint.				

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 41 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 28

DATE	Тімекеерек	Hours Task	<u>[</u>	<u>ACTIVITY</u>	AMOUNT
11/06/20	Sheila Birnbaum	0.30	L210	A104	405.00
	Review agreement between Debtors and UC (0.3).	CC regarding p	rivileg	ed motions	
11/09/20	Sheila Birnbaum	0.80	L210	A104	1,080.00
	Review newly filed pleadings (0.8); review m regarding same (0.7); review emails regarding	-		mails	
11/09/20	Sara Roitman	0.60	L210	A104	549.00
	Analyze plaintiffs' request for an en banc he appeal (.6).	aring in the N	egotiat	tion Class	
11/09/20	Danielle Gentin Stock	0.10	L210	A104	89.00
	Review correspondence regarding petition t negotiation class (0.1).	o 6th Circuit o	concerr	ning	
11/10/20	Sheila Birnbaum	0.70	L210	A104	945.00
	Review pleadings regarding approval of DOJ	resolution (0	.7).		
11/10/20	Paul LaFata	0.10	L210	A107	89.00
	Confer with local counsel regarding revisions representation (TN).	s to appearan	ce and		
11/11/20	Sheila Birnbaum	0.80	L210	A104	1,080.00
	Review response to motion to confirm DOJ r	esolution (0.8	3).		
11/12/20	Sheila Birnbaum	0.80	L210	A104	1,080.00
	Review responses to 9019 motion.				
11/15/20	Sheila Birnbaum	2.50	L210	A103	3,375.00
	Review and revise omnibus reply to 9019 mo	otion.			
11/15/20	Sheila Birnbaum	0.70	L210	A103	945.00
	Review stipulation regarding motion for pro	tective order.			
11/15/20	Sara Roitman	1.30		A103	1,189.50
	Review and revise summary of motions relative syndrome Plaintiffs' Motion for Class Certification	_	onatal	abstinence	
11/15/20	Mary Kim	2.80	L210	A104	2,240.00
	Review and summarize neonatal abstinence briefing.	syndrome cla	ass cert	cification	
11/15/20	Danielle Gentin Stock	1.30	L210	A104	1,157.00
	Review and comment on draft reply brief regarding the same (1.1); confer internally re			respond	
11/16/20	Sheila Birnbaum	0.80	L210	A104	1,080.00
	Review debtors Omnibus Reply in Support o Approving the DOJ resolution (0.8).	f Motion Auth	norizin	g and	
11/16/20	Shmuel Vasser	2.50	L210	A104	2,287.50
	Review pleadings regarding DOJ settlement	for impact on	litigati	ion.	

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 42 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 29

DATE	TIMEKEEPER	Hours T	- ASK	ACTIVITY	AMOUNT
11/17/20	Sheila Birnbaum	0.80	L210	A104	1,080.00
	Review voluntary injunction (0.5); review re impact on litigation (0.3).	vised bank	ruptcy ord	ler for	
11/18/20	Sheila Birnbaum	1.00	L210	A104	1,350.00
	Review court orders.				
11/23/20	Sheila Birnbaum	0.70	L210	A104	945.00
	Review motion to intervene by news media	(0.7).			
11/23/20	Hayden Coleman	2.60	L210	A104	2,379.00
	Review and analyze motion by non-consent documents (.6); review and analyze motion Jones and Boston Globe (.8); review and analyze and supporting documents (1.2).	to interver	ne in same	by Dow	
11/24/20	Sara Roitman	0.60	L210	A104	549.00
	Analyze settlement implications regarding e Negotiation Class (0.6).	n banc pet	tition rega	rding	
11/30/20	Jenna Newmark	1.60	L210	A104	1,368.00
	Review and analyze West Virginia neonatal for analysis of damages (1.6).	abstinence	syndrome	e complaint	
L210 SUBTOT	AL HOURS AND FEES:	27.40			28,859.50
L220 – Prelim	inary Injunctions/Provisional Remedies				
11/16/20	Danielle Gentin Stock	1.00	L220	A104	890.00
	Review and annotate Voluntary Injunction (1.0).			
11/17/20	Danielle Gentin Stock	0.20	L220	A105	178.00
	Correspond internally regarding Voluntary I	njunction.			
11/30/20	Danielle Gentin Stock	0.20	L220	A107	178.00
	Correspond with co-counsel regarding Volume	ntary Injun	ction (0.2)		
L220 SUBTOT	AL HOURS AND FEES:	1.40			1,246.00
L230 – Court	Mandated Conferences				
11/04/20	Sara Roitman	1.30	L230	A109	1,189.50
	Attend MDL Status conference (.8); draft su	mmary reg	garding sar	ne (.5).	
11/17/20	Sheila Birnbaum	7.50	L230	A109	10,125.00
	Attend Bankruptcy hearing before Judge Dra	ain.			
11/17/20	Hayden Coleman	7.50	L230	A109	6,862.50
	Attend Omnibus Hearing.				
11/17/20	Sara Roitman	7.50	L230	A109	6,862.50
	Attend Purdue hearing on DOJ settlement c	onfirmatio	n (7.5).		
11/17/20	Danielle Gentin Stock Attend virtual bankruptcy court conference.	7.40	L230	A109	6,586.00

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 43 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 30

<u>Date</u>	TIMEKEEPER	Hours Tas	<u>K</u>	ACTIVITY	AMOUNT
<u> </u>	Paul LaFata	4.10	_ L230	A109	3,649.00
	Attend court hearing on motions and disc privilege.	ussions on stat	us of dis	scovery and	
11/24/20	Sheila Birnbaum	1.00	L230	A109	1,350.00
	Attend plea hearing in NJ district court.				
11/24/20	Hayden Coleman	1.00	L230	A109	915.00
	Attend Purdue criminal plea hearing.				
L230 SUBTO	TAL HOURS AND FEES:	37.30			37,539.50
L310 – Writte	en Discovery				
11/01/20	Sheila Birnbaum	1.50	L310	A106	2,025.00
	Telephone conference with Purdue and P documents and discovery (1.2); telephone regarding documents (0.3).	-	_	-	
11/01/20	Theodore Yale	3.20	L310	A102	2,320.00
	Research and analysis regarding privilege	issues.			
11/01/20	Michelle Yeary	1.00	L310	A108	890.00
	Participate in telephone call with outside privileged document proposal with UCC.	counsel and cli	ent rega	ording	
11/02/20	Hayden Coleman	1.20	L310	A104	1,098.00
	Review and provide comments on counte with UCC regarding privileged documents	=	ntial ag	reement	
11/02/20	Sara Roitman	0.70	L310	A105	640.50
	Communicate with Dechert team regarding	ng discovery iss	ues.		
11/02/20	Michelle Yeary	0.50	L310	A105	445.00
	Communicate with Dechert team and clie proposal.	nt regarding pr	ivileged	document	
11/03/20	Sheila Birnbaum	0.50	L310	A104	675.00
	Review discovery e-mails (0.5).				
11/03/20	Danielle Gentin Stock	0.10	L310	A106	89.00
	Correspond with client regarding case law dispute (0.1).	governing priv	ilege do	ocument	
11/03/20	Danielle Gentin Stock	0.30	L310	A107	267.00
	Review correspondence from co-counsel document dispute (0.3).	and client regar	ding pr	ivileged	
11/04/20	Sara Roitman	0.90	L310	A105	823.50
	Communicate with Dechert team regarding	ng discovery.			
11/05/20	Hayden Coleman	0.40	L310	A106	366.00
	Communicate with DPW, Dechert and clied discovery disputes with UCC.	ent regarding se	ettlemer	nt of	

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 44 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 31

VALUES ON THIS INVOICE ARE BILLED IN USD

DATE	TIMEKEEPER	Hours TA	<u>ASK</u>	ACTIVITY	AMOUNT
11/12/20	Sara Roitman	0.60	L310	A105	549.00
	Communicate with Dechert team regarding of	discovery r	elated iss	ues.	
11/13/20	Sheila Birnbaum	0.80	L310	A104	1,080.00
	Review discovery motion file (0.8).				
11/16/20	Sheila Birnbaum	0.30	L310	A105	405.00
	Telephone conference with H. Coleman and issues.	D. Stock re	garding d	iscovery	
11/16/20	Sheila Birnbaum	0.30	L310	A107	405.00
	Telephone conference with Davis Polk regard syndrome discovery motion.	ding neona	tal abstin	ence	
11/16/20	Sheila Birnbaum	0.70	L310	A108	945.00
	Telephone conference with representative o babies regarding discovery issues (0.7).	f neonatal	abstinend	ce syndrome	
11/18/20	Sheila Birnbaum	0.80	L310	A108	1,080.00
	Telephone conference with representative o babies regarding discovery (0.8).	f neonatal	abstinend	ce syndrome	
11/18/20	Hayden Coleman	0.60	L310	A106	549.00
	Conference call with client and DPW regarding syndrome discovery request (0.6).	ng neonata	al abstiner	nce	
11/19/20	Hayden Coleman	1.30	L310	A104	1,189.50
	Review and respond to emails from outside of abstinence syndrome discovery requests (0.4 in support of its motion to compel production review and analyze statement of non-consermotion regarding privileged documents (0.3)	4); review and of privile of states	and analy: ged docu	ze UCC Reply ments (0.6);	
11/20/20	Hayden Coleman	0.80	L310	A108	732.00
	Plan for and participate in meet and confer v syndrome group regarding discovery request		tal abstin	ence	
11/20/20	Paul LaFata	0.10	L310	A108	89.00
	Confer with non-party counsel regarding doo	cument disc	covery.		
11/24/20	Paul LaFata	0.60	L310	A107	534.00
	Confer with co-defense counsel (0.3) and no third-party document discovery.	n-party coเ	unsel (0.3) regarding	
11/25/20	Danielle Gentin Stock	0.40	L310	A106	356.00
	Review and correspond with client regarding documents.	g previously	y produce	d	
L310 SUBTOTA	AL HOURS AND FEES:	17.60			17,552.50

L320 – Document Production	

11/01/20 Sheila Birnbaum 0.30 L320 A105 405.00

Telephone conference with Dechert lawyers regarding priviledged documents (0.3).

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Filed 02/11/21 Entered 02/11/21 12:25:06 Pg 45 of 92

Main Document

Invoice 1010003211 Page 32

<u>Date</u>	Тімекеерег	Hours Task		<u>ACTIVITY</u>	AMOUNT
11/01/20	Sheila Birnbaum	1.20	L320	A104	1,620.00
	Review stipulation and priviledged documer letters regarding privileged documents (0.4)		w e-m	ails and	
11/01/20	Danielle Gentin Stock	1.10	L320	A106	979.00
	Confer with client and co-counsel regarding	privileged doo	cumen	t dispute.	
11/01/20	Danielle Gentin Stock	1.60	L320	A105	1,424.00
	Confer internally and with client regarding r	next steps in do	ocume	nt dispute.	
11/01/20	Danielle Gentin Stock	0.60	L320	A104	534.00
	Review and revise proposed resolution of procorrespond with co-counsel and internally related case law (0.2).	•			
11/01/20	Paul LaFata	1.40	L320	A106	1,246.00
	Confer with client regarding strategy in and roll-off production.	response to de	emanc	for privilege	
11/02/20	Sheila Birnbaum	0.40	L320	A104	540.00
	Review letters to court regarding discovery	(0.4).			
11/02/20	Danielle Gentin Stock	1.90	L320	A106	1,691.00
	Confer with client regarding materials for the client regarding status of privilege motion (0)	•	5); con	fer with	
11/02/20	Danielle Gentin Stock	0.60	L320	A104	534.00
	Review materials relating to Monitor querie	es (0.6).			
11/02/20	Danielle Gentin Stock	0.20	L320	A105	178.00
	Confer internally regarding status of Monito	or productions	and re	eport (0.2).	
11/03/20	Danielle Gentin Stock	0.30	L320	A105	267.00
	Confer internally regarding privileged docur	ment dispute ((0.3).		
11/11/20	Sara Roitman	0.50	L320	A107	457.50
	Communicate with co-Defendants and team issues regarding Purdue documents.	n regarding End	do pro	duction	
11/13/20	Paul LaFata	0.30	L320	A107	267.00
	Confer with non-party counsel and co-defer document request (.1); analyze letter agree	_	-	- •	
11/16/20	Hope Freiwald	1.50	L320	A104	1,635.00
	Review neonatal abstinence syndrome clain discovery and documents (.7); prepare same		seekin	g certain	
11/18/20	Paul LaFata	0.10	L320	A107	89.00
	Confer with co-defense counsel regarding d from third party.	ocument shari	ng agr	reement	
11/19/20	Sara Roitman	0.40	L320	A107	366.00
	Communicate with co-counsel and Dechert production issues.	team regardin	g Endo	o document	

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 46 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 33

<u>Date</u>	TIMEKEEPER	Hours Tas	<u>sk</u>	ACTIVITY	AMOUNT
11/25/20	Paul LaFata	0.50	L320	A107	445.00
	Confer with non-party counsel (0.3) and conduction.	o-counsel (0.2)) regardii	ng non-party	
11/30/20	Danielle Gentin Stock	0.60	L320	A104	534.00
	Review correspondence regarding previou	sly produced	documer	nts (0.1).	
L320 SUBTO	TAL HOURS AND FEES:	13.50			13,211.50
L330 – Depos	sitions				
11/02/20	Hayden Coleman	1.50	L330	A106	1,372.50
	Communicate with client and outside cour and confidentiality designations for upcon application of protective order to deposition and correspondence with client regarding agreement with UCC regarding privileged	ning deposition on testimony (counter offers	ns (0.6) a (0.3); cor s to pote	nd nferences	
11/02/20	Danielle Gentin Stock	0.10	L330	A107	89.00
	Correspond internally and with co-counse	l regarding on	going de	positions.	
11/02/20	Paul LaFata	0.20	L330	A107	178.00
	Confer with co-defense counsel regarding	deposition str	rategy.		
11/02/20	Paul LaFata	0.30	L330	A106	267.00
	Confer with client and co-defense counsel	regarding pro	tective o	order.	
11/03/20	Hayden Coleman	0.40	L330	A105	366.00
	Communicate with Dechert team regarding	g UCC deposit	tions (0.4	.).	
11/03/20	Danielle Gentin Stock	0.20	L330	A105	178.00
	Correspond internally regarding ongoing d	lepositions (0.	2).		
11/04/20	Sheila Birnbaum	1.50	L330	A104	2,025.00
	Review depositions (0.8); review e-mails a (0.7).	nd materials o	on privile	ge dispute	
11/04/20	Hayden Coleman	1.60	L330	A105	1,464.00
	Conference and correspondence with D. G deposition (1.3); communicate with Deche (0.3).				
11/04/20	Hayden Coleman	4.90	L330	A104	4,483.50
	Review transcript and deposition summary transcript and deposition summary of M. To emails from client and DPW regarding redocuments (0.6).	Γimney (2.1); r	review ar	nd respond	
11/04/20	Mara Cusker Gonzalez	0.60	L330	A105	549.00
	Confer with litigation team regarding UCC regarding same (.3).	depositions (.	3); analy	ses	
11/04/20	Hope Freiwald	0.50	L330	A104	545.00
	Review summaries of UCC depositions.				

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 47 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 34

<u>Date</u>	TIMEKEEPER	Hours Ta	<u>sk</u>	ACTIVITY	AMOUNT
11/04/20	Erik Snapp	0.50	L330	A105	457.50
	Review and analyze deposition summaries (team regarding same (.1).	.4); correspo	ondence	with internal	
11/04/20	Danielle Gentin Stock	8.90	L330	A109	7,921.00
	Attend deposition of S. Baker.				
11/05/20	Sheila Birnbaum	0.80	L330	A104	1,080.00
	Review deposition testimony (0.8).				
11/05/20	Hayden Coleman	2.70	L330	A104	2,470.50
	Review transcript and summaries of S. Bake	r deposition	(2.7).		
11/05/20	Hayden Coleman	1.20	L330	A105	1,098.00
	Conference calls and emails with D. Stock remonitor report (1.2).	garding S. B	aker dep	oosition and	
11/05/20	Hope Freiwald	0.30	L330	A104	327.00
	Review UCC deposition summary of S. Baker	r.			
11/05/20	Erik Snapp	0.20	L330	A104	183.00
	Review and analyze summary of deposition	of Purdue e	mployee	٠.	
11/05/20	Alison Cooney	9.10	L330	A109	7,644.00
	Attend deposition of K. Sackler (9.1).				
11/05/20	Danielle Gentin Stock	0.70	L330	A105	623.00
	Correspond and confer internally regarding (0.7).	summary of	S. Baker	deposition	
11/06/20	Sheila Birnbaum	0.80	L330	A104	1,080.00
	Review K. Sackler deposition (0.8).				
11/06/20	Hayden Coleman	2.40	L330	A104	2,196.00
	Review K. Sackler deposition transcript and analyze summary of meet and confer call wi		-		
11/06/20	Mara Cusker Gonzalez	0.50	L330	A104	457.50
	Review and provide comments on summario	es of UCC de	position	s (.5).	
11/06/20	Mara Cusker Gonzalez	0.20	L330	A105	183.00
	Confer with litigation team regarding summ	aries of UCC	deposit	ions (.2).	
11/06/20	Hope Freiwald	0.50	L330	A104	545.00
	Review UCC deposition summaries of S. Bak	er and K. Sa	ckler.		
11/06/20	Nathan Hoffman	0.60	L330	A104	549.00
	Review and analyze UCC deposition summa	ries.			
11/06/20	Sara Roitman	0.90	L330	A105	823.50
	Communicate with Dechert team regarding implications for Purdue regarding same.	depositions	and litig	ation	
11/06/20	Erik Snapp	0.20	L330	A104	183.00
	Review and analyze summary of deposition	of former Pu	urdue en	nployee.	

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 48 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 35

11/06/20	DATE	TIMEKEEPER	Hours TA	<u>ASK</u>	ΑςτινιτΥ	<u>Amount</u>
11/06/20 Danielle Gentin Stock 0.50 L330 A105 A45.00	11/06/20	Alison Cooney	2.60	L330	A103	2,184.00
Confer internally regarding UCC depositions (0.5). 11/06/20 Danielle Gentin Stock 0.10 L330 A104 89.00 Review summary of K. Sackler deposition (0.1). 11/09/20 Sara Roitman 0.80 L330 A105 732.00 Communicate with Dechert team regarding depositions and strategy regarding same. 11/09/20 Sara Roitman 1.50 L330 A104 1,372.50 Review and analyze deposition transcripts and summaries for Purdue witness depositions deposition f M. Sackler (0.9). 11/09/20 Jenna Newmark 0.90 L330 A101 769.50 Prepare for upcoming deposition of M. Sackler (0.9). 11/10/20 Sheila Birnbaum 0.80 L330 A104 1,080.00 Review depositions (0.8). 11/10/20 Jenna Newmark 8.00 L330 A104 684.00 Appear for deposition of M. Sackler (8.0). 11/10/20 Jenna Newmark 8.00 L330 A101 684.00 Prepare for deposition of M. Sackler (0.8). 11/11/20 Sheila Birnbaum 0.80 L330 A104 1,080.00 Review deposition of M. Sackler (0.8). 11/11/20 Hayden Coleman 2.10 L330 A104 1,921.50 Review summary and transcript of M. Sackler deposition (2.1). 11/11/20 Mara Cusker Gonzalez 0.60 L330 A104 549.00 Review updated deposition status report and summaries (.4); confer with litigation team regarding upcoming UCC depositions (.2). 11/11/20 Jenna Newmark 0.30 L330 A104 549.00 A104 Danielle Gentin Stock 0.30 L330 A104 534.00 A104		Prepare summary and analysis of K. Sackler	deposition	(2.6).		
11/06/20 Danielle Gentin Stock 0.10 L330 A104 Review summary of K. Sackler deposition (0.1).	11/06/20	Danielle Gentin Stock	0.50	L330	A105	445.00
Review summary of K. Sackler deposition (0.1).		Confer internally regarding UCC depositions	(0.5).			
11/09/20 Sara Roitman 0.80 L330 A105 A1	11/06/20	Danielle Gentin Stock	0.10	L330	A104	89.00
Communicate with Dechert team regarding depositions and strategy regarding same. 11/09/20 Sara Roitman 1.50 L330 A104 1,372.50 Review and analyze deposition transcripts and summaries for Purdue witness depositions. 11/09/20 Jenna Newmark 0.90 L330 A101 769.50 Review depositions (0.8). 1330 A104 1,080.00 Review depositions (0.8). 1330 A104 1,080.00 Appear for deposition of M. Sackler (8.0). 1330 A109 6,840.00 Appear for deposition of M. Sackler (8.0). 11/10/20 Jenna Newmark 8.00 L330 A101 684.00 A101 A102 A		Review summary of K. Sackler deposition (0	.1).			
Tegarding same. 1.50	11/09/20	Sara Roitman	0.80	L330	A105	732.00
Review and analyze deposition transcripts and summaries for Purdue witness depositions. 11/09/20			depositions	and stra	tegy	
Mitness depositions.	11/09/20	Sara Roitman	1.50	L330	A104	1,372.50
Prepare for upcoming deposition of M. Sackler (0.9). 11/10/20 Sheila Birnbaum 0.80 L330 A104 1,080.00 Review depositions (0.8). 11/10/20 Jenna Newmark 8.00 L330 A109 6,840.00 Appear for deposition of M. Sackler (8.0).			nd summar	ies for Pu	rdue	
11/10/20 Sheila Birnbaum	11/09/20	Jenna Newmark	0.90	L330	A101	769.50
Review depositions (0.8).		Prepare for upcoming deposition of M. Sack	der (0.9).			
11/10/20 Jenna Newmark 8.00 L330 A109 6,840.00	11/10/20	Sheila Birnbaum	0.80	L330	A104	1,080.00
11/10/20 11/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20 19/10/20		Review depositions (0.8).				
11/10/20 Jenna Newmark Prepare for deposition of M. Sackler (0.8) 11/11/20 Sheila Birnbaum 0.80 L330 A104 1,080.00 Review deposition of M. Sackler (0.8). 11/11/20 Hayden Coleman 2.10 L330 A104 1,921.50 Review summary and transcript of M. Sackler deposition (2.1). 11/11/20 Mara Cusker Gonzalez 0.60 L330 A104 549.00 Review updated deposition status report and summaries (.4); confer with litigation team regarding upcoming UCC depositions (.2). 11/11/20 Jenna Newmark 0.30 L330 A103 256.50 Draft and revise summary of deposition of M. Sackler (0.3). 11/11/20 Danielle Gentin Stock 0.60 L330 A104 534.00 Review and analyze M. Sackler deposition (0.6). 11/11/20 Danielle Gentin Stock 0.30 L330 A107 267.00 Confer and correspond internally and with co-coursel resarding UCC depositions (0.3). 11/12/20 Mara Cusker Gonzalez 0.50 L330 A105 457.50 Confer with litigation team regarding upcoming UCC depositions. 1.50 L330 A104 1,372.50 11/12/20 Sara Roitman 1.50 L330 A104 1,372.50 11/12/20 L330 A104 L3372.50 L330 A104 L3372.50 L330 A104 L3372.50 L	11/10/20	Jenna Newmark	8.00	L330	A109	6,840.00
Prepare for deposition of M. Sackler (0.8) 11/11/20		Appear for deposition of M. Sackler (8.0).				
11/11/20 Sheila Birnbaum 0.80 L330 A104 1,080.00 11/11/20 Hayden Coleman 2.10 L330 A104 1,921.50 Review summary and transcript of M. Sackler deposition (2.1). 11/11/20 Mara Cusker Gonzalez 0.60 L330 A104 549.00 Review updated deposition status report and summaries (.4); confer with litigation team regarding upcoming UCC depositions (.2). 11/11/20 Jenna Newmark 0.30 L330 A103 256.50 Draft and revise summary of deposition of M. Sackler (0.3). 11/11/20 Danielle Gentin Stock 0.60 L330 A104 534.00 Review and analyze M. Sackler deposition (0.6). 11/11/20 Danielle Gentin Stock 0.30 L330 A107 267.00 Confer and correspond internally and with colspan="4">Confer with litigation team regarding upcoming UCC depositions	11/10/20	Jenna Newmark	0.80	L330	A101	684.00
Review deposition of M. Sackler (0.8). 11/11/20 Hayden Coleman 2.10 L330 A104 1,921.50 Review summary and transcript of M. Sackler deposition (2.1). 11/11/20 Mara Cusker Gonzalez 0.60 L330 A104 549.00 Review updated deposition status report and summaries (.4); confer with litigation team regarding upcoming UCC depositions (.2). 11/11/20 Jenna Newmark 0.30 L330 A103 256.50 Draft and revise summary of deposition of M. Sackler (0.3). 11/11/20 Danielle Gentin Stock 0.60 L330 A104 534.00 Review and analyze M. Sackler deposition (0.6). 11/11/20 Danielle Gentin Stock 0.30 L330 A107 267.00 Confer and correspond internally and with co-counsel regarding UCC depositions (0.3). 11/12/20 Mara Cusker Gonzalez 0.50 L330 A105 457.50 Confer with litigation team regarding upcoming UCC depositions. 11/12/20 Sara Roitman 1.50 L330 A104 1,372.50		Prepare for deposition of M. Sackler (0.8)				
11/11/20 Hayden Coleman Review summary and transcript of M. Sackler deposition (2.1). 11/11/20 Mara Cusker Gonzalez Review updated deposition status report and summaries (.4); confer with litigation team regarding upcoming UCC depositions (.2). 11/11/20 Jenna Newmark Draft and revise summary of deposition of M. Sackler (0.3). 11/11/20 Danielle Gentin Stock Review and analyze M. Sackler deposition (0.6). 11/11/20 Danielle Gentin Stock Review and correspond internally and with co-counsel regarding UCC depositions (0.3). 11/12/20 Mara Cusker Gonzalez Confer with litigation team regarding upcoming UCC depositions. 11/12/20 Sara Roitman 1.50 L330 A104 1,921.50 1,921.50 1330 A104 549.00	11/11/20	Sheila Birnbaum	0.80	L330	A104	1,080.00
Review summary and transcript of M. Sackler deposition (2.1). 11/11/20 Mara Cusker Gonzalez 0.60 L330 A104 549.00 Review updated deposition status report and summaries (.4); confer with litigation team regarding upcoming UCC depositions (.2). 11/11/20 Jenna Newmark 0.30 L330 A103 256.50 Draft and revise summary of deposition of M. Sackler (0.3). 11/11/20 Danielle Gentin Stock 0.60 L330 A104 534.00 Review and analyze M. Sackler deposition (0.6). 11/11/20 Danielle Gentin Stock 0.30 L330 A107 267.00 Confer and correspond internally and with co-counsel regarding UCC depositions (0.3). 11/12/20 Mara Cusker Gonzalez 0.50 L330 A105 457.50 Confer with litigation team regarding upcoming UCC depositions. 11/12/20 Sara Roitman 1.50 L330 A104 1,372.50		Review deposition of M. Sackler (0.8).				
11/11/20 Mara Cusker Gonzalez Review updated deposition status report and summaries (.4); confer with litigation team regarding upcoming UCC depositions (.2). 11/11/20 Jenna Newmark Draft and revise summary of deposition of M. Sackler (0.3). 11/11/20 Danielle Gentin Stock Review and analyze M. Sackler deposition (0.6). 11/11/20 Danielle Gentin Stock O.30 L330 A104 Sackler deposition (0.6). 11/11/20 Danielle Gentin Stock O.30 L330 A107 Confer and correspond internally and with co-counsel regarding UCC depositions (0.3). 11/12/20 Mara Cusker Gonzalez Confer with litigation team regarding upcoming UCC depositions. 11/12/20 Sara Roitman 1.50 L330 A104 1,372.50	11/11/20	Hayden Coleman	2.10	L330	A104	1,921.50
Review updated deposition status report and summaries (.4); confer with litigation team regarding upcoming UCC depositions (.2). 11/11/20 Jenna Newmark 0.30 L330 A103 256.50 Draft and revise summary of deposition of M. Sackler (0.3). 11/11/20 Danielle Gentin Stock 0.60 L330 A104 534.00 Review and analyze M. Sackler deposition (0.6). 11/11/20 Danielle Gentin Stock 0.30 L330 A107 267.00 Confer and correspond internally and with co-counsel regarding UCC depositions (0.3). 11/12/20 Mara Cusker Gonzalez 0.50 L330 A105 457.50 Confer with litigation team regarding upcoming UCC depositions. 11/12/20 Sara Roitman 1.50 L330 A104 1,372.50		Review summary and transcript of M. Sackle	er depositio	n (2.1).		
litigation team regarding upcoming UCC depositions (.2). 11/11/20 Jenna Newmark 0.30 L330 A103 256.50 Draft and revise summary of deposition of M. Sackler (0.3). 11/11/20 Danielle Gentin Stock 0.60 L330 A104 534.00 Review and analyze M. Sackler deposition (0.6). 11/11/20 Danielle Gentin Stock 0.30 L330 A107 267.00 Confer and correspond internally and with co-counsel regarding UCC depositions (0.3). 11/12/20 Mara Cusker Gonzalez 0.50 L330 A105 457.50 Confer with litigation team regarding upcoming UCC depositions. 11/12/20 Sara Roitman 1.50 L330 A104 1,372.50	11/11/20	Mara Cusker Gonzalez	0.60	L330	A104	549.00
Draft and revise summary of deposition of M. Sackler (0.3). 11/11/20 Danielle Gentin Stock 0.60 L330 A104 534.00 Review and analyze M. Sackler deposition (0.6). 11/11/20 Danielle Gentin Stock 0.30 L330 A107 267.00 Confer and correspond internally and with co-counsel regarding UCC depositions (0.3). 11/12/20 Mara Cusker Gonzalez 0.50 L330 A105 457.50 Confer with litigation team regarding upcoming UCC depositions. 11/12/20 Sara Roitman 1.50 L330 A104 1,372.50		·			nfer with	
11/11/20 Danielle Gentin Stock 0.60 L330 A104 534.00 Review and analyze M. Sackler deposition (0.6). 11/11/20 Danielle Gentin Stock 0.30 L330 A107 267.00 Confer and correspond internally and with co-counsel regarding UCC depositions (0.3). 11/12/20 Mara Cusker Gonzalez 0.50 L330 A105 457.50 Confer with litigation team regarding upcoming UCC depositions. 11/12/20 Sara Roitman 1.50 L330 A104 1,372.50	11/11/20	Jenna Newmark	0.30	L330	A103	256.50
Review and analyze M. Sackler deposition (0.6). 11/11/20 Danielle Gentin Stock 0.30 L330 A107 267.00 Confer and correspond internally and with co-counsel regarding UCC depositions (0.3). 11/12/20 Mara Cusker Gonzalez 0.50 L330 A105 457.50 Confer with litigation team regarding upcoming UCC depositions. 11/12/20 Sara Roitman 1.50 L330 A104 1,372.50		Draft and revise summary of deposition of N	႔. Sackler ((0.3).		
11/11/20 Danielle Gentin Stock 0.30 L330 A107 267.00 Confer and correspond internally and with co-counsel regarding UCC depositions (0.3). 11/12/20 Mara Cusker Gonzalez 0.50 L330 A105 457.50 Confer with litigation team regarding upcoming UCC depositions. 11/12/20 Sara Roitman 1.50 L330 A104 1,372.50	11/11/20	Danielle Gentin Stock	0.60	L330	A104	534.00
Confer and correspond internally and with co-counsel regarding UCC depositions (0.3). 11/12/20 Mara Cusker Gonzalez 0.50 L330 A105 457.50 Confer with litigation team regarding upcoming UCC depositions. 11/12/20 Sara Roitman 1.50 L330 A104 1,372.50		Review and analyze M. Sackler deposition (0	0.6).			
depositions (0.3). 11/12/20 Mara Cusker Gonzalez 0.50 L330 A105 457.50 Confer with litigation team regarding upcoming UCC depositions. 11/12/20 Sara Roitman 1.50 L330 A104 1,372.50	11/11/20	Danielle Gentin Stock	0.30	L330	A107	267.00
Confer with litigation team regarding upcoming UCC depositions. 11/12/20 Sara Roitman 1.50 L330 A104 1,372.50			co-counsel r	egarding	UCC	
11/12/20 Sara Roitman 1.50 L330 A104 1,372.50	11/12/20	Mara Cusker Gonzalez	0.50	L330	A105	457.50
		Confer with litigation team regarding upcon	ning UCC de	positions		
Review and analyze deposition summaries for Purdue witnesses.	11/12/20	Sara Roitman	1.50	L330	A104	1,372.50
		Review and analyze deposition summaries f	or Purdue v	vitnesses.		

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 49 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 36

<u>Date</u>	Тімекеерег	Hours Task		<u>ACTIVITY</u>	AMOUNT
11/12/20	Erik Snapp	0.20	L330	A105	183.00
	Correspondence with internal team regarding depositions	ng upcoming P	urdue	fact witness	
11/12/20	Jenna Newmark	0.90	L330	A103	769.50
	Draft/revise summary of deposition of M. Sa	ockler (0.9).			
11/12/20	Danielle Gentin Stock	0.40	L330	A106	356.00
	Correspond internally and with client regard	ling UCC depos	sition	testimony.	
11/12/20	Danielle Gentin Stock	0.70	L330	A104	623.00
	Review and analyze M. Sackler UCC depositi	on testimony.			
11/13/20	Erik Snapp	0.40	L330	A104	366.00
	Review work product regarding upcoming P	. Boer depositi	on		
11/13/20	Jenna Newmark	1.80	L330	A103	1,539.00
	Draft and revise M. Sackler deposition sumn	nary (1.8).			
11/13/20	Danielle Gentin Stock	0.30	L330	A105	267.00
	Correspond internally regarding UCC deposi	tions.			
11/14/20	Jenna Newmark	1.50	L330	A103	1,282.50
	Draft/revise summary of deposition of M. Sa	ockler (1.5).			
11/15/20	Mara Cusker Gonzalez	0.50	L330	A103	457.50
	Review and revise draft summary of recent of member.	deposition of f	ormer	board	
11/15/20	Erik Snapp	0.60	L330	A107	549.00
	Correspondence with internal team, co-cour (0.2); review work product regarding same (P. Boe	er deposition	
11/15/20	Jenna Newmark	0.30	L330	A103	256.50
, ,	Review and revise summary of deposition of	f M. Sackler (0.	.3).		
11/15/20	Danielle Gentin Stock	0.20	-	A104	178.00
	Review correspondence related to UCC depo	osition (0.2).			
11/16/20	Erik Snapp	1.30	L330	A109	1,189.50
	Prepare for and attend P. Boer deposition.				•
11/16/20	Danielle Gentin Stock	0.80	L330	A104	712.00
	Review and analyze deposition testimony (0	.5); summarize			
11/16/20	Danielle Gentin Stock	0.40		A107	356.00
	Correspond with co-counsel and client regar	ding deposition	n test	imony (0.4).	
11/16/20	Danielle Gentin Stock	0.20	L330	A107	178.00
	Correspond with other counsel regarding U(CC depositions	(0.2).		
11/18/20	Hayden Coleman	0.20		A105	183.00
-	Conference call with Dechert team regarding	g depositions.			
11/18/20	Danielle Gentin Stock	0.30	L330	A107	267.00
-	Correspond with co-counsel and internally r	egarding UCC			
	•	•	-		

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 50 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 37

DATE	TIMEKEEPER	Hours TA	<u>ISK</u>	<u>ACTIVITY</u>	AMOUNT
11/18/20	Danielle Gentin Stock	0.50	L330	A105	445.00
	Confer internally regarding UCC depositions status of depositions (0.3).	(0.2); confe	er interna	ally regarding	
11/18/20	Paul LaFata	0.30	L330	A105	267.00
	Confer with counsel regarding deposition st	rategy.			
11/19/20	Sheila Birnbaum	0.80	L330	A104	1,080.00
	Review deposition of R. Sackler (0.8).				
11/19/20	Hayden Coleman	3.50	L330	A109	3,202.50
	Attend R. Sackler deposition.				
11/19/20	Hayden Coleman	0.80	L330	A103	732.00
	Provide reports on R. Sackler deposition.				
11/19/20	Sara Roitman	2.00	L330	A104	1,830.00
	Review and analyze R. Sackler deposition tra	anscript.			
11/19/20	Danielle Gentin Stock	0.60	L330	A105	534.00
	Confer internally regarding UCC depositions	and claims	analysis.		
11/19/20	Danielle Gentin Stock	0.70	L330	A107	623.00
	Confer with co-counsel regarding upcoming correspond internally regarding the same (0	•	ition (0.6);	
11/19/20	Danielle Gentin Stock	4.50	L330	A109	4,005.00
	Attend virtual R. Sackler deposition.				
11/19/20	Paul LaFata	0.30	L330	A104	267.00
	Analyze document discovery in advance of f	act depositi	ion.		
11/20/20	Sheila Birnbaum	1.30	L330	A104	1,755.00
	Review Sackler deposition.				
11/20/20	Hayden Coleman	5.00	L330	A109	4,575.00
	Attend deposition of R. Sackler.				
11/20/20	Hayden Coleman	2.30	L330	A104	2,104.50
	Review transcript of M. Sackler deposition a review deposition report and summary of R				
11/20/20	Mara Cusker Gonzalez	0.40	L330	A105	366.00
	Confer with litigation counsel regarding dep	ositions.			
11/20/20	Sara Roitman	2.50	L330	A104	2,287.50
	Review and analyze R. Sackler deposition tradeposition summary.	anscript and	l R. Abrar	ms	
11/20/20	Sara Roitman	1.50	L330	A105	1,372.50
	Communicate with Dechert team regarding related settlement and DOJ implications for		depositi	ions and	
11/20/20	Paul LaFata	9.00	L330	A109	8,010.00
	Prepare for and attend deposition of R. Abra	ams (9.0).			

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Filed 02/11/21 Entered 02/11/21 12:25:06 Pg 51 of 92 Main Document

Invoice 1010003211

Page 38

<u>Date</u>	Тімекеерег	Hours Task		<u>ACTIVITY</u>	AMOUNT
11/20/20	Paul LaFata	0.70	L330	A107	623.00
	Confer with co-defense counsel (0.4) and clie	ent (0.3) rega	rding R	١.	
	Abrams deposition.				
11/23/20	Sheila Birnbaum	1.00	L330	A104	1,350.00
	Review former employee deposition transcri	pts (1.0).			
11/23/20	Sara Roitman	0.60	L330	A107	549.00
	Communicate with Dechert team and co-Det Washington AG case and deposition regarding	_	rding 6	expert in	
11/23/20	Danielle Gentin Stock	0.30	L330	A107	267.00
	Confer with co-counsel regarding UCC depos	ition.			
11/23/20	Danielle Gentin Stock	0.60	L330	A105	534.00
	Confer internally regarding UCC depositions	(.3).			
11/23/20	Danielle Gentin Stock	0.30	L330	A104	267.00
	Review and analyze deposition summaries.				
11/23/20	Danielle Gentin Stock	0.10	L330	A107	89.00
	Correspond with co-counsel regarding depos	sition attenda	nce.		
11/23/20	Paul LaFata	0.40	L330	A105	356.00
	Confer with counsel regarding depositions.				
11/24/20	Sheila Birnbaum	0.80	L330	A104	1,080.00
	Review former employee deposition transcri	pts (0.8).			
11/24/20	Hayden Coleman	3.20	L330	A104	2,928.00
	Review and analyze draft of C. Landau depos	ition (3.2).			
11/24/20	Sara Roitman	0.70	L330	A104	640.50
	Review and analyze summary of C. Landau d	eposition.			
11/24/20	Sara Roitman	0.50	L330	A105	457.50
	Communicate with Dechert team regarding	depositions.			
11/24/20	Jenna Newmark	5.00	L330	A109	4,275.00
	Appear for deposition of J. White (5.0).				
11/24/20	Danielle Gentin Stock	7.70	L330	A109	6,853.00
	Attend virtual deposition of Dr. C. Landau.				
11/24/20	Danielle Gentin Stock	1.50	L330	A104	1,335.00
	Prepare and circulate summary of Dr. Landa	u deposition.			
11/25/20	Hayden Coleman	0.30	L330	A107	274.50
	Communicate with Dechert, client and DPW	regarding de	positio	ns (0.3).	
11/25/20	Jenna Newmark	0.20	L330	A103	171.00
	Draft summary of deposition of J. White (0.2).			
11/25/20	Danielle Gentin Stock	0.30	L330	A107	267.00
	Correspond with co-counsel regarding UCC of	lepositions (0	.3).		

19-23649-shl Doc 2376

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Filed 02/11/21 Entered 02/11/21 12:25:06 Pg 52 of 92

Main Document

Invoice 1010003211 Page 39

<u>Date</u>	Тімекеерек	Hours Tas	K ACTIVITY	Amount
11/29/20	Erik Snapp	0.20	L330 A104	183.00
	Review, analyze work product summa	ries of Purdue dep	ositions.	
11/29/20	Sarah Magen	0.20	L330 A104	171.00
	Review MA AG records to prepare for	C. Landau call.		
11/29/20	Sarah Magen	0.90	L330 A105	769.50
	Communicate internally regarding MA C. Landau call.	AG records reviev	v in preparation for	
11/30/20	Sheila Birnbaum	0.50	L330 A107	675.00
	Attend call with counsel regarding pre	paration of Landau	ı (0.5).	
11/30/20	Sarah Magen	0.60	L330 A105	513.00
	Communicate internally regarding C. L	andau testimony p	oreparation.	
11/30/20	Sarah Magen	4.20	L330 A103	3,591.00
	Prepare document analysis regarding (C. Landau testimor	ny preparation.	
L330 SUBTOT	AL HOURS AND FEES:	142.80		131,359.50
L350 – Discov	ery Motions			
11/16/20	Sheila Birnbaum	0.70	L350 A104	945.00
	Review motion for discovery by neona	tal abstinence syn	drome babies (0.7).	
L350 SUBTOT	AL HOURS AND FEES:	0.70		945.00
L410 – Fact W	/itnesses			
11/30/20	Hayden Coleman	7.50	L410 A104	6,862.50
	Plan for and participate in C. Landau p (5.3); address open issues raised by sa	•	ongressional Hearing	
L410 SUBTOT	AL HOURS AND FEES:	7.50		6,862.50
TOTAL HOUR	S AND FEES	637.80		USD 630,071.00

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Main Document

Invoice 1010003211 Page 40

TIMEKEEPER SUMMARY:							
TIMEKEEPER	TITLE	RATE	<u>Hours</u>	Amoun			
S. Birnbaum	Partner	1,350.00	139.40	188,190.00			
H. Freiwald	Partner	1,090.00	4.00	4,360.00			
H. Coleman	Partner	915.00	123.80	113,277.00			
M. Cusker Gonzalez	Partner	915.00	18.20	16,653.00			
N. Hoffman	Partner	915.00	0.60	549.0			
S. Roitman	Partner	915.00	116.90	106,963.5			
E. Snapp	Partner	915.00	3.60	3,294.0			
S. Vasser	Partner	915.00	2.50	2,287.5			
S. Magen	Associate	855.00	5.90	5,044.5			
I. Newmark	Associate	855.00	38.80	33,174.0			
A. Cooney	Associate	840.00	11.70	9,828.0			
M. Kim	Associate	800.00	2.80	2,240.0			
Zanello	Associate	800.00	0.40	320.0			
A. Clark	Associate	725.00	3.00	2,175.0			
Γ. Yale	Associate	725.00	21.70	15,732.5			
C. Boisvert	Counsel	890.00	15.10	13,439.0			
D. Gentin Stock	Counsel	890.00	93.70	83,393.0			
P. LaFata	Counsel	890.00	20.90	18,601.0			
. Tam	Counsel	890.00	9.50	8,455.0			
M. Yeary	Counsel	890.00	1.50	1,335.0			
A. Capobianco-Ranallo	Legal Assistant	200.00	3.00	600.0			
M. Stone	Legal Assistant	200.00	0.80	160.0			
C. Cohen	Other	185.00	0.10	18.5			
TOTALS			637.90	USD 630,089.5			



REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. 201 Tresser Blvd. Stamford, CT 06901 February 3, 2021 Invoice Number 1010003211

Firm Client Matter Number: 399631.178405

Client Name: Purdue Pharma L.P.

Matter Name: Mediation & Settlement, Claims Evaluation, and Operations

Electronic Billing Number: 20210003064

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICE......USD 505,186.00

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003211) in the check memo. Mail to: Dechert LLP $\,\mid\,$ P.O. Box 7247-6643 Philadelphia, PA $\,\mid\,$ 19170-6643



Purdue Pharma L.P. 201 Tresser Blvd. Stamford, CT 06901 February 10, 2021 Invoice Number 1010003210

Firm Client Matter Number: 399631.161942

Client Name: Purdue Pharma L.P. Matter Name: Municipality Suits

Electronic Billing Number: 20170001582

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL FEES THIS INVOICE	20,398.00
Less 20% Discount	(4,079.60)
NET TOTAL FEES THIS INVOICE	16,318.40
TOTAL AMOUNT DUE FOR THIS INVOICE	USD 16,318.40

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account

Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.161942 Invoice 1010003210 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

PROFESSIONAL SERVICES RENDERED:

<u>Date</u>	TIMEKEEPER	Hours Tas	<u>K</u> <u>ACTIVITY</u>	<u>AMOUNT</u>
L120 - Analy	sis/Strategy			
11/04/20	Christopher Boisvert	0.80	L120 A103	712.00
	Draft and revise Pennsylvania AG Sta	tus Report.		
11/16/20	Lindsay Zanello	0.10	L120 A105	80.00
	Communicate internally regarding W	est Virginia cases.		
11/19/20	Hayden Coleman	0.60	L120 A107	549.00
	Communicate with outside counsel r conferences and emails with Dechert (0.4).			
11/20/20	Sarah Magen	0.30	L120 A104	256.50
	Review recent CT AG and municipalit	y filings.		
L120 SUBTO	TAL HOURS AND FEES:	1.80		1,597.50
L190 - Other	Case Assessment, Development and A	dministration		
11/03/20	Denise Neris	0.80	L190 A101	124.00
	Monitor, review, and summarize new coordinated litigation and communic same.	=	_	
11/04/20	Denise Neris	1.10	L190 A101	170.50
	Monitor, review, and summarize new coordinated litigation and communic same.	-	=	
11/05/20	Denise Neris	0.80	L190 A101	124.00
	Monitor, review, and summarize new coordinated litigation and communic same.	-	-	
11/06/20	Denise Neris	1.00	L190 A101	155.00
	Monitor, review, and summarize new coordinated litigation and communic same.		_	
11/09/20	Denise Neris	1.30	L190 A101	201.50
	Monitor, review, and summarize new coordinated litigation and communic same.		_	
11/10/20	Alyssa Clark	0.40	L190 A105	290.00
	Email to H. Coleman regarding case s	tatus (0.4, NY).		

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 57 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.161942 Invoice 1010003210 Page 3

DATE	Тімекеерек	Hours Tas	K ACTIVITY	<u>Amount</u>
11/10/20	Denise Neris	0.90	L190 A101	139.50
	Monitor, review, and summarize new plead coordinated litigation and communicate wit same.	_	=	
11/12/20	Denise Neris	0.80	L190 A101	124.00
	Monitor, review, and summarize new plead coordinated litigation and communicate wit same.	_	=	
11/13/20	Denise Neris	0.60	L190 A101	93.00
	Monitor, review, and summarize new plead coordinated litigation and communicate wit same.	_	_	
11/17/20	Denise Neris	1.10	L190 A101	170.50
	Monitor, review, and summarize new plead coordinated litigation and communicate wit same.	_	_	
11/18/20	Denise Neris	1.10	L190 A101	170.50
	Monitor, review, and summarize new plead coordinated litigation and communicate wit same.	_	_	
11/19/20	Denise Neris	0.70	L190 A101	108.50
	Monitor, review, and summarize new plead coordinated litigation and communicate wit same.	_	=	
11/20/20	Denise Neris	0.40	L190 A101	62.00
	Monitor, review, and summarize new plead coordinated litigation and communicate wit same.	_	_	
11/23/20	Denise Neris	0.50	L190 A101	77.50
	Monitor, review, and summarize new plead coordinated litigation and communicate wit same.	•	•	
11/24/20	Denise Neris	0.60	L190 A101	93.00
	Monitor, review, and summarize new plead coordinated litigation and communicate wit same.	_	_	
11/25/20	Denise Neris	0.50	L190 A101	77.50
	Monitor, review, and summarize new plead coordinated litigation and communicate wit same.	_	=	
L190 SUBTOT	AL HOURS AND FEES:	12.60		2,181.00

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 58 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.161942 Invoice 1010003210 Page 4

<u>Date</u>	TIMEKEEPER	Hours Tas	<u>ACTIVITY</u>	AMOUNT
L210 – Plead	ings			
11/12/20	Hayden Coleman	2.20	L210 A104	2,013.00
	Review and analyze Frye orders issued	in NY AG consolic	dated cases (2.2).	
11/12/20	Mara Cusker Gonzalez	0.50	L210 A103	457.50
	Draft and revise report to client, banks regarding Frye motions (.5).	ruptcy team, and I	itigation team	
11/12/20	Mara Cusker Gonzalez	0.70	L210 A103	640.50
	Review New York Court's order on Def Plaintiffs' experts in the coordinated li	•	tions to exclude	
11/12/20	Alyssa Clark	2.60	L210 A104	1,885.00
	Review and summarize Frye order for	team and client (2	.6, NY).	
11/24/20	Lindsey Cohan	0.70	L210 A104	623.00
	Review and file notice of bankruptcy s discussions and correspondence regar			
L210 SUBTO	TAL HOURS AND FEES:	6.70		5,619.00
L310 - Writt	en Discovery			
11/02/20	Sarah Magen	0.60	L310 A104	513.00
	Review and strategize regarding NJ and	d RI discovery issu	es.	
11/10/20	Danielle Torrice	0.30	L310 A104	60.00
	Review and analyze third-party product correspondence (PA, .3).	ction documents a	nd related	
11/13/20		ction documents a	nd related L310 A104	513.00
11/13/20	correspondence (PA, .3).	0.60	L310 A104	513.00
	correspondence (PA, .3). Sarah Magen	0.60	L310 A104	513.00 1,086.00
L310 SUBTO	correspondence (PA, .3). Sarah Magen Review correspondence regarding RI A	0.60 AG discovery issue	L310 A104	
L310 SUBTO	correspondence (PA, .3). Sarah Magen Review correspondence regarding RI A TAL HOURS AND FEES:	0.60 AG discovery issue	L310 A104	
L310 SUBTO	correspondence (PA, .3). Sarah Magen Review correspondence regarding RI A TAL HOURS AND FEES: ment Production	0.60 AG discovery issue: 1.50 2.60 Endo in MDL for p	L310 A104 S. L320 A103 Orivilege and	1,086.00
L310 SUBTO	correspondence (PA, .3). Sarah Magen Review correspondence regarding RI A TAL HOURS AND FEES: ment Production Christopher Boisvert Review documents to be produced by	0.60 AG discovery issue: 1.50 2.60 Endo in MDL for p	L310 A104 S. L320 A103 Orivilege and	1,086.00
L310 SUBTO	correspondence (PA, .3). Sarah Magen Review correspondence regarding RI A TAL HOURS AND FEES: ment Production Christopher Boisvert Review documents to be produced by confidentiality concerns (1.6); draft co TAL HOURS AND FEES:	0.60 aG discovery issue: 1.50 2.60 Endo in MDL for prespondence reg	L310 A104 S. L320 A103 Orivilege and	1,086.00 2,314.00
L320 - Docum 11/13/20 L320 SUBTO	correspondence (PA, .3). Sarah Magen Review correspondence regarding RI A TAL HOURS AND FEES: ment Production Christopher Boisvert Review documents to be produced by confidentiality concerns (1.6); draft co TAL HOURS AND FEES: Trial Preparation and Support	2.60 Endo in MDL for prespondence reg	L310 A104 s. L320 A103 orivilege and arding same (1.0).	2,314.00 2,314.00
L310 SUBTO	correspondence (PA, .3). Sarah Magen Review correspondence regarding RI A TAL HOURS AND FEES: ment Production Christopher Boisvert Review documents to be produced by confidentiality concerns (1.6); draft co TAL HOURS AND FEES: Trial Preparation and Support Nicholas Dean	2.60 Endo in MDL for prespondence reg 2.60 2.10	L310 A104 s. L320 A103 privilege and arding same (1.0).	1,086.00 2,314.00
L320 - Docum 11/13/20 L320 SUBTO L440 - Other 11/09/20	correspondence (PA, .3). Sarah Magen Review correspondence regarding RI A TAL HOURS AND FEES: ment Production Christopher Boisvert Review documents to be produced by confidentiality concerns (1.6); draft co TAL HOURS AND FEES: Trial Preparation and Support Nicholas Dean Analyze proposed documents for pre-t	2.60 Endo in MDL for prespondence reg 2.60 2.10 trial stipulation in	L310 A104 S. L320 A103 Orivilege and arding same (1.0). L440 A104 WV.	2,314.00 2,314.00 766.50
L320 - Docum 11/13/20 L320 SUBTO	correspondence (PA, .3). Sarah Magen Review correspondence regarding RI A TAL HOURS AND FEES: ment Production Christopher Boisvert Review documents to be produced by confidentiality concerns (1.6); draft co TAL HOURS AND FEES: Trial Preparation and Support Nicholas Dean Analyze proposed documents for pre-t Nicholas Dean	2.60 Endo in MDL for prespondence reg 2.60 2.10 2.10 2.10 2.10 2.10 2.10	L310 A104 s. L320 A103 privilege and arding same (1.0). L440 A104 WV. L440 A104	2,314.00 2,314.00
L320 - Docur 11/13/20 L320 SUBTO L440 - Other 11/09/20 11/18/20	correspondence (PA, .3). Sarah Magen Review correspondence regarding RI A TAL HOURS AND FEES: ment Production Christopher Boisvert Review documents to be produced by confidentiality concerns (1.6); draft co TAL HOURS AND FEES: Trial Preparation and Support Nicholas Dean Analyze proposed documents for pre-tally in the pr	2.60 Endo in MDL for prespondence reg 2.60 2.10 trial stipulation in 3.50 trial stipulation in	L310 A104 S. L320 A103 Drivilege and arding same (1.0). L440 A104 WV. L440 A104 W.VA.	1,086.00 2,314.00 2,314.00 766.50 1,277.50
L320 - Docum 11/13/20 L320 SUBTO L440 - Other 11/09/20	correspondence (PA, .3). Sarah Magen Review correspondence regarding RI A TAL HOURS AND FEES: ment Production Christopher Boisvert Review documents to be produced by confidentiality concerns (1.6); draft co TAL HOURS AND FEES: Trial Preparation and Support Nicholas Dean Analyze proposed documents for pre-t Nicholas Dean	2.60 Endo in MDL for prespondence reg 2.60 2.10 trial stipulation in 3.50 trial stipulation in 2.30	L310 A104 s. L320 A103 privilege and arding same (1.0). L440 A104 WV. L440 A104 W.VA. L440 A104	2,314.00 2,314.00 766.50

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 59 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.161942

Invoice 1010003210 Page 5

<u>Dате</u> 11/25/20	TIMEKEEPER Paul LaFata Analyze documents proposed for trial st		<u>ACTIVITY</u> .440 A104	<u>AMOUNT</u> 1,869.00
11/30/20	Paul LaFata Analyze proposed trial exhibits for preti		.440 A104	2,848.00
L440 SUBTO	TAL HOURS AND FEES:	13.20		7,600.50
TOTAL HOU	RS AND FEES	38.40		USD 20,398.00

TIMEKEEPER SUMMARY:							
TIMEKEEPER	TITLE	RATE	Hours	Amount			
H. Coleman	Partner	915.00	2.80	2,562.00			
M. Cusker Gonzalez	Partner	915.00	1.20	1,098.00			
S. Magen	Associate	855.00	1.50	1,282.50			
L. Zanello	Associate	800.00	0.10	80.00			
A. Clark	Associate	725.00	3.00	2,175.00			
N. Dean	Staff Attorney	365.00	7.90	2,883.50			
C. Boisvert	Counsel	890.00	3.40	3,026.00			
L. Cohan	Counsel	890.00	0.70	623.00			
P. LaFata	Counsel	890.00	5.30	4,717.00			
D. Torrice	Legal Assistant	200.00	0.30	60.00			
D. Neris	Project Assistant	155.00	12.20	1,891.00			
TOTALS			38.40	USD 20,398.00			



REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. 201 Tresser Blvd. Stamford, CT 06901 February 10, 2021 Invoice Number 1010003210

Firm Client Matter Number: 399631.161942

Client Name: Purdue Pharma L.P. Matter Name: Municipality Suits

Electronic Billing Number: 20170001582

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 16,318.40

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003210) in the check memo. Mail to: Dechert LLP $\,\mid\,$ P.O. Box 7247-6643 Philadelphia, PA $\,\mid\,$ 19170-6643



Purdue Pharma L.P. 201 Tresser Blvd. Stamford, CT 06901 February 10, 2021 Invoice Number 1010003213

Firm Client Matter Number: 399631.178406

Client Name: Purdue Pharma L.P.

Matter Name: Fee Applications and Related Expenses

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICE	80
NET TOTAL FEES THIS INVOICE	80
Less 20% Discount(5,522.7	⁷ 0)
TOTAL FEES THIS INVOICE	50

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178406 Invoice 1010003213 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

PROFESSIONAL SERVICES RENDERED:

<u>Date</u>	TIMEKEEPER	Hours Task	ΑςτινιτΥ	<u>Amount</u>	
B160 - Fee/I	Employment Applications				
11/02/20	Matthew Stone	2.80	B160 A103	560.00	
	Review and edit October invoices to confor	m to U.S. Trust	ee guidelines.		
11/03/20	Matthew Stone	0.60	B160 A105	120.00	
	Communicate internally regarding matter of application.	lescriptions for	interim fee		
11/05/20	Matthew Stone	0.30	B160 A103	60.00	
	Review and revise patent matter description	ns for interim f	ee application.		
11/06/20	Matthew Stone	2.70	B160 A103	540.00	
	Review and revise October invoices to conf	orm to U.S. Tru	stee guidelines.		
11/09/20	Sara Roitman	2.50	B160 A104	2,287.50	
	Draft matter descriptions for Debtors' third analyze past bills regarding same (.4).	fee application	n (2.1); review and		
11/09/20	Matthew Stone	1.40	B160 A103	280.00	
	Review and revise Dechert interim fee appl	ication (1.4).			
11/10/20	Hayden Coleman	1.50	B160 A103	1,372.50	
	Review and revise third interim fee applicate	tion (1.5).			
11/10/20	Sara Roitman	2.00	B160 A104	1,830.00	
	Draft matter descriptions for Dechert third review and analyze prior fee statements re				
11/10/20	Matthew Stone	5.70	B160 A103	1,140.00	
	Review and revise Dechert interim fee appl	ication (5.7).			
11/11/20	Shmuel Vasser	2.00	B160 A104	1,830.00	
	Review certain issues regarding draft 3rd in	terim fee appli	cation.		
11/11/20	Matthew Stone	3.70	B160 A103	740.00	
	Review and revise Dechert interim fee appl	ication (3.7).			
11/12/20	Hayden Coleman	2.00	B160 A103	1,830.00	
	Review and revise October bills (1.4); review application (0.6).	w and revise 3d	l interim fee		
11/12/20	Matthew Stone	1.20	B160 A103	240.00	
	Review and revise Dechert interim fee appl	ication (1.2).			
11/12/20	Matthew Stone	0.80	B160 A105	160.00	
	Communicate with accounting (.5) and H. Coleman regarding Dechert interim fee application (.3).				
11/13/20	Shmuel Vasser	0.50	B160 A105	457.50	
	Review emails regarding rate issues (0.5).				

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 63 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178406 Invoice 1010003213 Page 3

DATE	TIMEKEEPER	Hours Tas	SK	ACTIVITY	AMOUNT
11/13/20	Shmuel Vasser	2.20	— В160	A103	2,013.00
	Review draft 3rd interim fee application (2.2).			
11/13/20	Katherine Norman	0.50	B160	A105	282.50
	Call with S. Vasser and B. Stone to discuss the	ird interim f	fee appli	cation (.5).	
11/13/20	Matthew Stone	1.40	B160	A103	280.00
	Revise interim fee application and exhibits (1 regarding same (.1).	L.3); commu	unicate v	vith S. Vasser	
11/14/20	Matthew Stone	1.50	B160	A103	300.00
	Revise interim fee application (1.5).				
11/14/20	Matthew Stone	0.10	B160	A105	20.00
	Communicate with S. Vasser regarding interi	m fee appli	cation (.:	1).	
11/15/20	Shmuel Vasser	1.00	B160	A103	915.00
	Review 3rd interim fee application (.4); revis	e same (.6).	i		
11/15/20	Matthew Stone	1.10	B160	A103	220.00
	Revise interim fee application (1.1).				
11/15/20	Matthew Stone	0.30	B160	A105	60.00
	Communicate with S. Vasser and S. Abrams r (.3).	regarding in	terim fe	e application	
11/16/20	Matthew Stone	0.50	B160	A104	100.00
	File Dechert interim fee application with ban service of same (.2).	kruptcy cou	urt (.3); a	rrange for	
11/17/20	Matthew Stone	1.60	B160	A103	320.00
	Review and edit October invoices regarding I	U.S. Trustee	e guidelir	nes.	
11/19/20	Matthew Stone	1.40	B160	A103	280.00
	Review and edit October invoices regarding I	U.S. Trustee	e guidelir	nes.	
11/20/20	Matthew Stone	2.80	B160	A103	560.00
	Review and edit October invoices regarding I	U.S. Trustee	e guidelir	nes.	
11/23/20	Danielle Gentin Stock	1.50	B160	A106	1,335.00
	Confer with client regarding billing for Purdu	e matter.			
11/23/20	Matthew Stone	5.50	B160	A103	1,100.00
	Review and edit October time entries to con (5.5).	form to U.S	. Trustee	guidelines	
11/23/20	Matthew Stone	0.30	B160	A105	60.00
	Communicate with D. Gentin-Stock regarding applications (.3).	g professior	nals' inte	rim fee	
11/24/20	Katherine Norman	0.40	B160	A105	226.00
	Call with B. Stone regarding fee statements (B. Stone and accounting regarding same (.2).		orrespor	ndence with	
11/24/20	Matthew Stone	0.80	B160	A103	160.00
	Review and edit October time entries to con (.7).	form to U.S	. Trustee	e guidelines	

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 64 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178406 Invoice 1010003213 Page 4

DATE	TIMEKEEPER	Hours T	ASK ACTIVITY	AMOUNT
11/24/20	Matthew Stone	0.20	B160 A105	40.00
	Call with C. Norman regarding Octol	ber fee statement (.2).	
11/30/20	Shmuel Vasser	0.20	B160 A105	183.00
	Emails with Dechert team regarding	October fee stater	nent.	
11/30/20	Katherine Norman	0.30	B160 A105	169.50
	Call with B. Stone (.1) and email constatements.	respondence (.2) re	egarding October fee	
11/30/20	Katherine Norman	2.40	B160 A104	1,356.00
	Review and revise October invoices	in connection with	fee statement (2.4).	
B160 SUBTO	TAL HOURS AND FEES:	55.70		23,427.50
B165 – Budg	eting (case)			
11/11/20	Shmuel Vasser	1.70	B165 A105	1,555.50
	Discuss litigation budget for 2021 (0 bankruptcy budget (1.0).	.7); review issue re	garding update	
11/16/20	Shmuel Vasser	1.00	B165 A103	915.00
	Prepare bankruptcy budget (1.0).			
11/16/20	Shmuel Vasser	0.70	B165 A105	640.50
	Discuss staffing plan with Dechert to budget (0.2).	eam (0.5); internal e	emails regarding IP	
11/16/20	Matthew Stone	0.30	B165 A105	60.00
	Communicate with S. Vasser regard interim period (.3).	ing budget and staf	fing plan for the next	
11/17/20	Matthew Stone	0.30	B165 A105	60.00
	Communicate with S. Vasser regard	ing proposed budge	et.	
11/18/20	Shmuel Vasser	1.00	B165 A103	915.00
	Finalize updated budget and staffing	g plan.		
11/18/20	Matthew Stone	0.20	B165 A103	40.00
	Finalize budget (.1); communicate w	vith S. Vasser regard	ding same (.1).	
B165 SUBTO	TAL HOURS AND FEES:	5.20		4,186.00
TOTAL HOU	RS AND FEES	60.90		USD 27,613.50

19-23649-shl Doc 2376

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178406

Filed 02/11/21 Entered 02/11/21 12:25:06 Pg 65 of 92

Main Document

Invoice 1010003213 Page 5

TIMEKEEPER SUMMARY:					
TIMEKEEPER	<u>Title</u>	<u> Rате</u>	Hours	Amount	
H. Coleman	Partner	915.00	3.50	3,202.50	
S. Roitman	Partner	915.00	4.50	4,117.50	
S. Vasser	Partner	915.00	10.30	9,424.50	
K. Norman	Associate	565.00	3.60	2,034.00	
D. Gentin Stock	Counsel	890.00	1.50	1,335.00	
M. Stone	Legal Assistant	200.00	37.50	7,500.00	
TOTALS			60.90	USD 27,613.50	



REMITTANCE AND PAYMENT INSTRUCTIONS

For guestions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. 201 Tresser Blvd. Stamford, CT 06901 February 10, 2021 Invoice Number 1010003213

Firm Client Matter Number: 399631.178406

Client Name: Purdue Pharma L.P.

Matter Name: Fee Applications and Related Expenses

Electronic Billing Number: 20190002705

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 22,090.80

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003213) in the check memo. Mail to: Dechert LLP $\,\mid\,$ P.O. Box 7247-6643 Philadelphia, PA $\,\mid\,$ 19170-6643



Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 10, 2021 Invoice Number 1010003215

Firm Client Matter Number: 379612.156278

Client Name: Purdue Pharma L.P.

Matter Name: (477C1) (13-MP-0017US03) Reduction of Alpha, Beta-Unsaturated Ketone Levels in Morphinan

Derivative

Electronic Billing Number: 20170001301

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL FEES THIS INVOICE	9,270.00
Less 8% Discount	(741.60)
NET TOTAL FEES THIS INVOICE	8,528.40
TOTAL DISBURSEMENTS THIS INVOICE	640.00
TOTAL AMOUNT DUE FOR THIS INVOICE	USD 9,168.40

Payment by Wire or ACH

Bank Name: Citi Private Bank Bank Address: 153 East 53rd St., New York, NY Account Name: Dechert LLP Main Account

Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 68 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.156278 Invoice 1010003215 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

PROFESSIONAL SERVICES RENDERED:

<u>Date</u>	TIMEKEEPER	Hours Ta	<u>sk</u>	ACTIVITY	<u>Amount</u>
P260 – Intelle	ctual Property				
11/06/20	Blaine Hackman	1.00	P260	A103	740.00
	Conference with the Examiner regarding the Statement (0.3); review documents cited in Statement (0.4); conference with S. Breland literature (0.3).	the Informa	tion Disc	losure	
11/06/20	Sherrice Breland	0.80	P260	A103	228.00
	Discussion with B. Hackman regarding reject Disclosure Statement (0.3); review of art dis Statements with the USPTO in the 477US an communicate with A. Arias regarding review disclosed (0.1).	closed in Inf d 477C1 app	formatior plications	n Disclosure s (0.4);	
11/11/20	Sherrice Breland	4.60	P260	A103	1,311.00
	Review of art not considered by Examiner (C from related families involved in litigation for Information Disclosure Statement (4.3); disc	or filing in su	ıpplemen	tal	
11/12/20	Sherrice Breland	3.50	P260	A103	997.50
	Continue search regarding art from related filing in supplemental Information Disclosur with B. Hackman (0.1).			_	
11/12/20	Donna Marks	0.30	P260	A101	91.50
	Review Applicant-Initiated Interview Summa Office (0.1); communicate same to B. Hackn calendar database (0.1).	-			
11/13/20	Blaine Hackman	0.40	P260	A104	296.00
	Review documents from S. Breland relating examiner (0.2); review the examiner interview examiner (0.2).				
11/13/20	Sherrice Breland	3.10	P260	A110	883.50
	Review of Examiner Interview Summary (0.1 Information Disclosure Statement and PTO/downloading of art to be disclosed to USPTO Information Disclosure Statement and PTO/(0.1).	SB08 (1.5); o (1.4); forw	complete ard Supp	lemental	
11/17/20	Blaine Hackman	0.20	P260	A105	148.00
	Correspond with S. Breland regarding the in and review complied references.	formation d	isclosure	statement	

Firm Matter Number: 379612.156278

Client Name: Purdue Pharma L.P.

Filed 02/11/21 Entered 02/11/21 12:25:06

Main Document Pg 69 of 92

VALUES ON THIS INVOICE ARE BILLED IN USD

Invoice 1010003215 Page 3

DATE	Тімекеерег	Hours TA	<u>sk</u>	ACTIVITY	Amount
 11/19/20	Blaine Hackman	0.80	P260	A104	592.0
	Prepare revisions to the draft Inform Examiner Interview Summary (0.7); of filing of the Information Disclosure S	conference with S. E			
11/19/20	Sherrice Breland	0.40	P260	A103	114.00
	Teleconference with B. Hackman (0. Statement and PTO-SB/08 (0.2); precommunicate to Maiwald regarding (0.1).	pare and forward fo	llow-up		
11/20/20	Blaine Hackman	2.10	P260	A104	1,554.00
	Review the list of references cited an (0.8); conference with S. Breland reg Disclosure Statement for filing (0.4); Disclosure Statement (0.9).	arding finalizing the	e Informa	tion	
11/20/20	Sherrice Breland	4.10	P260	A103	1,168.50
	discussion with B. Hackman regardin IPDAS (0.5); further revisions to information discuss and forward revised docume finalize, file and upload information documents with the U.S. Patent and System (2.5).	rmation disclosure s ints to B. Hackman f disclosure statemer	statemen for review nt and rel	t (0.3); v (0.1); ated	
11/21/20	Sherrice Breland	1.70	P260	A103	484.50
	Continue filing and uploading art cite with the U.S. Patent and Trademark organization of prosecution history (Office Electronic Fil			
11/23/20	Donna Marks	0.30	P260	A101	91.50
	Review Response to Summary of Exa Information Disclosure Statement as update same in calendar database (0	filed with U.S. Pate			
11/25/20	Sherrice Breland	1.00	P260	A103	285.00
	Prepare draft letter to client regarding related documents (0.5); discuss letter forward letter, Information Disclosur client (0.2); organization of prosecut	er with B. Hackman re Statement and re	(0.1); fin	alize and cuments to	
11/25/20	Sherrice Breland	1.00	P260	A103	285.00
	Prepare draft letter to client regarding discuss letter with B. Hackman (0.1); Examiner Interview Summary to clien history and correspondence (0.2).	finalize and forwar	d letter a	nd	
P260 SUBTO	TAL HOURS AND FEES:	25.30			9,270.00

19-23649-shl Doc 2376

Client Name: Purdue Pharma L.P.

Firm Matter Number: 379612.156278

Filed 02/11/21 Entered 02/11/21 12:25:06 Pg 70 of 92

Main Document

Page 4

Invoice 1010003215

VALUES ON THIS INVOICE ARE BILLED IN USD

DATE **TIMEKEEPER** Hours Task **ACTIVITY AMOUNT**

TIMEKEEPER SUMMARY:					
TIMEKEEPER	<u>Title</u>	RATE	Hours	AMOUNT	
B. Hackman	Associate	740.00	4.50	3,330.00	
D. Marks	Legal Assistant	305.00	0.60	183.00	
S. Breland	Legal Assistant	285.00	20.20	5,757.00	
TOTALS			25.30	USD 9,270.00	

DISBURSEMENTS:

DESCRIPTION	A MOUNT
Filing Fees and Related Filing Fees and Related - VENDOR: U.S. Patent and Trademark EXTENSION FOR RESPONSE WITHIN SECOND MONTH	640.00
	640.00
TOTAL DISBURSEMENTS	USD 640.00



REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 10, 2021 Invoice Number 1010003215

Firm Client Matter Number: 379612.156278

Client Name: Purdue Pharma L.P.

Matter Name: (477C1) (13-MP-0017US03) Reduction of Alpha, Beta-Unsaturated Ketone Levels in Morphinan

Derivative

Electronic Billing Number: 20170001301

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 9,168.40

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003215) in the check memo. Mail to: Dechert LLP $\,\mid\,$ P.O. Box 7247-6643 Philadelphia, PA $\,\mid\,$ 19170-6643



Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 10, 2021 Invoice Number 1010003216

Firm Client Matter Number: 379612.165623

Client Name: Purdue Pharma L.P.

Matter Name: (502US) (18-MT-0001US02) Sleep Disorder Treatment and Prevention

Electronic Billing Number: 20190002322

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL FEES THIS INVOICE	13,084.00
Less 8% Discount	(1,046.72)
NET TOTAL FEES THIS INVOICE	12,037.28
TOTAL AMOUNT DUE FOR THIS INVOICE	USD 12,037.28

Payment by Wire or ACH

Bank Name: Citi Private Bank Bank Address: 153 East 53rd St., New York, NY Account Name: Dechert LLP Main Account

Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.165623 Invoice 1010003216 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>Date</u>	TIMEKEEPER	Hours TA	ACTIVITY	<u>Amount</u>	
P260 – Intell	ectual Property				
11/06/20	Blaine Hackman	1.50	P260 A104	1,110.00	
	Research case law relevant to the clain	n strategy.			
11/06/20	Donna Marks	0.30	P260 A101	91.50	
	Review Notice of Publication received communicate same B. Hackman (0.1); (0.1).				
11/09/20	Blaine Hackman	1.40	P260 A103	1,036.00	
	Prepare revisions to the chart summar assignment information, and proposed	•	•		
11/09/20	Sherrice Breland	0.50	P260 A103	142.50	
	Study of file (0.1); review of formality of formality documents to B. Hackman for application and determine status of Astronogramization of prosecution history (0.	r review (0.1); resignments in tha	view of PCT		
11/10/20	Blaine Hackman	1.40	P260 A103	1,036.00	
	Prepare the preliminary amendments to the claims based on the analyses of priority documents.				
11/11/20	Blaine Hackman	1.80	P260 A103	1,332.00	
	Conference with S. Abrams regarding t claims (1.4).	he claim strategy	(0.4); prepare draft		
11/16/20	Blaine Hackman	1.60	P260 A104	1,184.00	
	Analyze the disclosure of the as-filed n the draft claims and preliminary amen		pplication to prepare		
11/16/20	Sherrice Breland	1.30	P260 A103	370.50	
	Study file (0.1); review Notice of Public Hackman (0.1); prepare draft letter to (0.4); download U.S. Publication (0.1); Notice of Publication and U.S. Publicat correspondence and prosecution histo	client regarding Newsise, finalize an ion to client (0.2)	Notice of Publication and forward letter,		
11/16/20	Donna Marks	0.20	P260 A101	61.00	
	Review email to client forwarding Noti calendar database (0.1).	ce of Publication	(0.1); update same in		
11/17/20	Blaine Hackman	0.90	P260 A103	666.00	
	Prepare revisions to the draft claims (C specification support for the draft clair		summary of		
11/20/20	Blaine Hackman	1.00	P260 A103	740.00	
	Prepare explanatory email to S. Abram amendments (0.3); prepare additional				

Firm Matter Number: 379612.165623

Client Name: Purdue Pharma L.P.

Filed 02/11/21 Entered 02/11/21 12:25:06 Pg 74 of 92

Main Document

Invoice 1010003216 Page 3

VALUES ON THIS INVOICE ARE BILLED IN USD

DATE	TIMEKEEPER	Hours Tas	<u>к</u> 4	<u>ACTIVITY</u>	AMOUNT
11/23/20	Samuel Abrams	2.50	P260 A	\103	2,212.50
	Review and revise claims regarding preli	minary amendm	ent.		
11/24/20	Samuel Abrams	2.00	P260 A	\104	1,770.00
	Review preliminary amendment.				
11/25/20	Blaine Hackman	0.50	P260 A	\103	370.00
	Revise preliminary amendment (0.3); prothe preliminary amendment (0.2).	epare an email to	o W. Yang	regarding	
11/30/20	Blaine Hackman	1.30	P260 A	\103	962.00
	Conference with S. Abrams regarding the claims based on comments from W. Yan preliminary amendment and responding	g (0.4); prepare	papers for	filing the	
P260 SUBTOT	AL HOURS AND FEES:	18.20			13,084.00
	_				
TOTAL HOURS	S AND FEES	18.20			USD 13,084.00

TIMEKEEPER SUMMARY:					
TIMEKEEPER	<u>Title</u>	RATE	Hours	AMOUNT	
S. Abrams	Partner	885.00	4.50	3,982.50	
B. Hackman	Associate	740.00	11.40	8,436.00	
D. Marks	Legal Assistant	305.00	0.50	152.50	
S. Breland	Legal Assistant	285.00	1.80	513.00	
TOTALS			18.20	USD 13,084.00	



REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 10, 2021 Invoice Number 1010003216

Firm Client Matter Number: 379612.165623

Client Name: Purdue Pharma L.P.

Matter Name: (502US) (18-MT-0001US02) Sleep Disorder Treatment and Prevention

Electronic Billing Number: 20190002322

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 12,037.28

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003216) in the check memo. Mail to: Dechert LLP $\,\mid\,$ P.O. Box 7247-6643 Philadelphia, PA $\,\mid\,$ 19170-6643



Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 10, 2021 Invoice Number 1010003217

Firm Client Matter Number: 379612.165625

Client Name: Purdue Pharma L.P.

Matter Name: (481US) (16-MT-0003US03) Treatment and Prevention of Sleep Disorders

Electronic Billing Number: 20190002321

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account

Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.165625 Invoice 1010003217 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>Date</u>	TIMEKEEPER	Hours Tas	<u>ACTIVITY</u>	<u>Amount</u>	
P260 – Intellectual Property					
11/09/20	Blaine Hackman	1.50	P260 A104	1,110.00	
	Analyze the specification and assignment prepare and overview summary of the proof of S. Abrams.	_			
11/10/20	Samuel Abrams	2.50	P260 A101	2,212.50	
	Review and revise claims (1.8); prepare (0.7).	for teleconference	ce with Dr. Hackman		
11/11/20	Samuel Abrams	3.00	P260 A101	2,655.00	
	Review and revise claims (2.0); prepare with Dr. Hackman regarding same.	for (0.2) and tele	econference (0.8)		
11/16/20	Sherrice Breland	0.80	P260 A110	228.00	
	Review file (0.1); review correspondence from Maiwald regarding request for art cited in instant application (0.1); prepare documents for forwarding to Maiwald for submission to the Israeli Patent Office (0.5); communicate with B. Hackman regarding same (0.1).				
P260 SUBTO	TAL HOURS AND FEES:	7.80		6,205.50	
TOTAL HOUF	RS AND FEES	7.80		USD 6,205.50	
	=				

TIMEKEEPER SUMMARY:					
TIMEKEEPER	<u>Title</u>	RATE	Hours	<u>Amount</u>	
S. Abrams	Partner	885.00	5.50	4,867.50	
B. Hackman	Associate	740.00	1.50	1,110.00	
S. Breland	Legal Assistant	285.00	0.80	228.00	
TOTALS			7.80	USD 6,205.50	



REMITTANCE AND PAYMENT INSTRUCTIONS

For guestions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 10, 2021 Invoice Number 1010003217

Firm Client Matter Number: 379612.165625

Client Name: Purdue Pharma L.P.

Matter Name: (481US) (16-MT-0003US03) Treatment and Prevention of Sleep Disorders

Electronic Billing Number: 20190002321

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 5,709.06

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003217) in the check memo. Mail to: Dechert LLP $\,\mid\,$ P.O. Box 7247-6643 Philadelphia, PA $\,\mid\,$ 19170-6643



Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 10, 2021 Invoice Number 1010003218

Firm Client Matter Number: 379612.168206

Client Name: Purdue Pharma L.P.

Matter Name: (478D2C1) (14-PS-0018US07) Acetate Salt of Buprenorphine and Methods for Preparing

Buprenorphine

Electronic Billing Number: 20190002532

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICE	USD 844.40
TOTAL DISBURSEMENTS THIS INVOICE	320.00
NET TOTAL FEES THIS INVOICE	524.40
Less 8% Discount	(45.60)
TOTAL FEES THIS INVOICE	570.00

Payment by Wire or ACH

Bank Name: Citi Private Bank Bank Address: 153 East 53rd St., New York, NY Account Name: Dechert LLP Main Account

Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 80 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.168206 Invoice 1010003218 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

PROFESSIONAL SERVICES RENDERED:

<u>Date</u>	TIMEKEEPER	Hours Task	<u>C</u>	<u>AMOUNT</u>	
P260 – Intelled	ctual Property				
11/16/20	Sherrice Breland	2.00	P260	570.00	
	Study Filing Receipt newly received from USPTO (0.1); prepare correspondence to client regarding Filing Receipt (0.5); discuss and forward draft to B. Hackman for review (0.1); finalize and forward letter and Filing Receipt to client (0.2); study Notice to File Missing Parts newly received from USPTO (0.1); prepare correspondence to client regarding Notice to File Missing Parts (0.5); discuss and forward draft letter to B. Hackman for review (0.1); finalize and forward letter and Notice to File Missing Parts (0.2); organization of correspondence and prosecution history (0.2).				
P260 SUBTOTA	AL HOURS AND FEES:	2.00		570.00	
TOTAL HOURS AND FEES		2.00		USD 570.00	

TIMEKEEPER SUMMARY:				
TIMEKEEPER	TITLE	<u> Rате</u>	Hours	AMOUNT
S. Breland	Legal Assistant	285.00	2.00	570.00
TOTALS			2.00	USD 570.00

DESCRIPTION	<u>Amount</u>
Filing Fees and Related	
Filing Fees and Related - VENDOR: U.S. Patent and Trademark BASIC FILING FEE - UTILITY	320.00
	320.00
TOTAL DISBURSEMENTS	USD 320.00

19-23649-shl Doc 2376

Filed 02/11/21 Entered 02/11/21 12:25:06 Pg 81 of 92

Invoice 1010003218

Main Document

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.168206

Page 3

VALUES ON THIS INVOICE ARE BILLED IN USD



REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 10, 2021 Invoice Number 1010003218

Firm Client Matter Number: 379612.168206

Client Name: Purdue Pharma L.P.

Matter Name: (478D2C1) (14-PS-0018US07) Acetate Salt of Buprenorphine and Methods for Preparing

Buprenorphine

Electronic Billing Number: 20190002532

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 844.40

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003218) in the check memo. Mail to: Dechert LLP $\,\mid\,$ P.O. Box 7247-6643 Philadelphia, PA $\,\mid\,$ 19170-6643



Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 10, 2021 Invoice Number 1010003219

Firm Client Matter Number: 379612.168216

Client Name: Purdue Pharma L.P.

Matter Name: (478D1) (14-PS-0018US05) Acetate Salt of Buprenorphine and Methods for Preparing

Buprenorphine

Electronic Billing Number: 20190002533

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL FEES THIS INVOICE	431.50
Less 8% Discount	(34.52)
NET TOTAL FEES THIS INVOICE	396.98
TOTAL AMOUNT DUE FOR THIS INVOICE	USD 396.98

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.168216 Invoice 1010003219 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>Date</u>	<u>TIMEKEEPER</u>	Hours Task	<u>K</u>	<u>AMOUNT</u>
P260 – Intell	ectual Property			
11/03/20	Sherrice Breland	1.30	P260	370.50
	Study file (0.1); review Issue Notific client regarding same (0.5); discuss review (0.1); finalize and forward le organization of correspondence an	s and forward draft to I etter and Issue Notifica	B. Hackman for ation to client (0.2);	
11/04/20	Donna Marks	0.20	P260	61.00
	Review email to client forwarding I calendar database (0.1).	ssue Notification (0.1)	; update same in	
P260 SUBTO	TAL HOURS AND FEES:	1.50		431.50
TOTAL HOURS AND FEES		1.50		USD 431.50

TIMEKEEPER SUMMARY:				
<u>TIMEKEEPER</u>	<u>Title</u>	RATE	Hours	<u>Amount</u>
D. Marks	Legal Assistant	305.00	0.20	61.00
S. Breland	Legal Assistant	285.00	1.30	370.50
TOTALS			1.50	USD 431.50



REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 10, 2021 Invoice Number 1010003219

Firm Client Matter Number: 379612.168216

Client Name: Purdue Pharma L.P.

Matter Name: (478D1) (14-PS-0018US05) Acetate Salt of Buprenorphine and Methods for Preparing

Buprenorphine

Electronic Billing Number: 20190002533

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 396.98

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003219) in the check memo. Mail to: Dechert LLP | P.O. Box 7247-6643 Philadelphia, PA | 19170-6643



Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 10, 2021 Invoice Number 1010003221

Firm Client Matter Number: 379612.394684

Client Name: Purdue Pharma L.P. Matter Name: General Patent Matters Electronic Billing Number: 1000001538

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL FEES THIS INVOICE	85.50
Less 8% Discount	(6.84)
NET TOTAL FEES THIS INVOICE	
TOTAL AMOUNT DUE FOR THIS INVOICE	USD 78.66

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 87 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.394684 Invoice 1010003221

Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

DATE	<u>TIMEKEEPER</u>	Hours Tas	SK ACTIVITY	AMOUNT
P260 - Intell	ectual Property			
11/12/20	Sherrice Breland	0.30	P260 A103	85.50
	Review correspondence regarding failur status of patent (0.2).	e of annuity payr	ment (0.1); review	
P260 SUBTO	TAL HOURS AND FEES:	0.30		85.50
	_			
TOTAL HOURS AND FEES		0.30		USD 85.50

TIMEKEEPER SUMMARY:				
TIMEKEEPER	TITLE	<u>Rate</u>	<u>Hours</u>	AMOUNT
S. Breland	Legal Assistant	285.00	0.30	85.50
TOTALS			0.30	USD 85.50



REMITTANCE AND PAYMENT INSTRUCTIONS

For guestions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P. One Stamford Forum Stamford, CT 06901 February 10, 2021 Invoice Number 1010003221

Firm Client Matter Number: 379612.394684

Client Name: Purdue Pharma L.P. Matter Name: General Patent Matters Electronic Billing Number: 1000001538

Professional Services Rendered Through November 30, 2020

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 78.66

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010003221) in the check memo. Mail to: Dechert LLP $\,\mid\,$ P.O. Box 7247-6643 Philadelphia, PA $\,\mid\,$ 19170-6643

19-23649-shl Doc 2376 Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 89 of 92

EXHIBIT B

Expenses

Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 90 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 399631.178405 Invoice 1010003211 Page 41

VALUES ON THIS INVOICE ARE BILLED IN USD

DESCRIPTION	AMOUNT
Overtime Dinner Expense	
Overtime Dinner Expense - VENDOR: SeamlessWeb Professional Solutions, Inc. Overtime Dinner Expense Invoice: SL-307-6, Order 601013255212476. Vend or: Natsumi	20.00
	20.00
Filing Fees and Related	
Filing Fees and Related - E-filing for DC Purdue matter - 10/09/2020	36.88
Filing Fees and Related Lopez Luis ALexisNexis FileServe - Ale rt Fee - Alerts	20.00
	56.88
Court Costs	
Court Costs - Telephonic appearances at Nov. 17 hearing - 11/17/2020	70.00
Court Costs - Telephonic appearances at Nov. 17 hearing - 11/17/2020	70.00
Court Costs - Telephonic appearances at Nov. 17 hearing - 11/17/2020	70.00
	210.00
Taxi Fare	
Taxi Fare - VENDOR: Elite Car Service 10/20/2020 Coleman 176 BROADWAY	39.60
<u> </u>	39.60
Westlaw Search Fees	
Westlaw Search Fees	764.82
_	764.82
DOCKET FEES	70
Docket Fees Blaw Trans: DT - D.N.J 2:20-cr-01028	2.70
Docket Fees BLaw Trans: DT - D.N.J 2:20-cr-01028	2.70
<u>-</u>	5.40
Federal Express Charges	
Federal Express Charges	17.70
	17.70
	•
TOTAL DISBURSEMENTS	USD 1,114.40

19-23649-shl Doc 2376

Client Name: Purdue Pharma L.P. Firm Matter Number: 399630.163596

Filed 02/11/21 Entered 02/11/21 12:25:06 Pg 91 of 92

Main Document

Invoice 1010003214 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

DESCRIPTION	<u>AMOUNT</u>
Consultants Fees	
Consultants Fees - VENDOR: Ankura Consulting Group, LLC Invoice# CI-020512 Dated	89,962.88
10/27/2020 for September 2020 services	
Consultants Fees - VENDOR: Ankura Consulting Group, LLC INVOICE NO. CI-021718	219.69
11/16/20 For October 2020 services	
Consultants Fees - VENDOR: Ankura Consulting Group, LLC INVOICE NO. CI-022354	88,397.85
11/24/20 For October 2020 services	
	178,580.42
TOTAL DISBURSEMENTS	USD 178,580.42

19-23649-shl Doc 2376 Filed 02/11/21 Entered 02/11/21 12:25:06 Main Document Pg 92 of 92

Client Name: Purdue Pharma L.P. Firm Matter Number: 379612.168318 Invoice 1010003220 Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

DESCRIPTION	Amount
Filing Fees and Related	
Filing Fees and Related - VENDOR: U.S. Patent and Trademark UTILITY ISSUE FEE	1,000.00
	1,000.00
TOTAL DISBURSEMENTS	USD 1,000.00